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ABSTRACT 
Quorum sensing in bacteria is a process of cell-to-cell communication facilitated by small 
molecules called autoinducers. Interspecies quorum sensing is facilitated by the autoinducer 
AI-2. The enzyme LuxS catalyzes the formation of AI-2 from S-ribosyl homocysteine (SRH) 
in a wide variety of bacterial species. Inhibition of LuxS would therefore inhibit interspecies 
quorum sensing. The goal of this project is to establish biochemical assays for the evaluation 
of small molecules as potential LuxS inhibitors. The first assay is a conventional colorimetric 
assay that utilizes Ellman’s reagent to quantify the homocysteine byproduct of DPD 
production by LuxS. For this assay purified enzyme (LuxS), a negative control (LuxS C84A), 
and the substrate (SRH) are required. His-tagged LuxS and LuxS C84A have been purified 
from overexpression cultures of Escherichia coli cells freshly transformed with a vector 
harboring the appropriate gene. Chemically-synthesized and quantified SRH was also 
acquired after extensive efforts of our fellow organic chemists. Ellman’s assay was then 
performed to determine the activity of house-purified LuxS. This assay would be optimized 
in future to be performed in 96 well plate to avoid excess consumption of enzyme and 
substrate. In addition, a fluorescence proximity assay is envisioned for the evaluation of a 
subset of LuxS inhibitors that function by preventing protein dimerization. This assay 
requires that purified LuxS be conjugated with an appropriate fluorophore, likely via a 
cysteine residue. An appropriate LuxS variant i.e. LuxS Y71C to which a single fluorophore 
would attach was acquired after extensive troubleshooting. An appropriate fluorophore would 
be attached to this LuxS variant for determination of potential dimerization inhibition.   
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CHAPTER 1: INTRODUCTION 
 
Behaviors such as bioluminescence, biofilm formation, and motility are examples of 
behaviors most effective when performed collectively by a group of bacteria.1 The regulation 
of gene expression to perform these behavioral responses in response to cell population in 
bacteria is termed quorum sensing.1 The basic process of quorum sensing involves three 
prime characters: (1) synthase, (2) signal, and (3) sensor. The synthase plays the key part 
because it initiates the process of quorum sensing by synthesizing small-molecule signals 
called autoinducers (AI). These signals, when received by the sensors at a threshold level, 
initiate gene expression for the aforementioned collective behavioral responses. (see Fig. 1.1) 
 
Fig. 1.1 | Quorum Sensing Model. The signals synthesized by the synthases are received by the sensor initiating 
a chain of reactions leading to bacterial behavioral responses. 
 
1.1 |  Quorum Sensing System Two: Interspecies Quorum Sensing. As of now, two major 
quorum sensing systems have been identified: System One which involves intraspecies 
communication and System Two involving interspecies communication.2 System Two 
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quorum sensing is present in a wide variety of bacterial species.3 Virulence expression in 
many human pathogens is one of the behavioral responses co-ordinated by System Two 
quorum sensing.4 Virulence is the ability of bacteria to cause disease, and examples of 
bacterial species that utilize System Two quorum sensing for pathogenesis are listed in Table 
1.1. Before targeting the host for pathogenesis interspecies quorum sensing helps these 
pathogenic bacteria to successfully infect the host by gathering a bacterial population density 
capable of overwhelming the immune system of the host. Therefore, System Two quorum 
sensing is a very apt target for the development of novel antimicrobial drugs against bacterial 
species that functions as human pathogens. 
 
Table 1.1 | Bacterial Species Utilizing Quorum Sensing System Two for Pathogenesis. Some of the examples 
of the diseases caused by different bacterial species are shown.3 
Species Diseases  
Actinobacillus actinomycetemcomitans Periodontal disease 
Borrelia burgdorferi Lyme disease 
Campylobacter jejuni Food poisoning 
Clostridium perfringens Food poisoning 
Escherichia coli Intestinal and extra-intestinal infections 
Neisseria meningitides Bacterial meningitis (epidemic) 
Porphyromonas gingivalis Periodontal disease 
 
To facilitate System Two quorum sensing, the enzyme S-ribosylhomocysteinase (LuxS), 
universally found in all bacterial species & involved in interspecies quorum sensing, acts as 
synthase to produce small molecule signals called autoinducer-2 (AI-2).5,3 The AI-2 signal is 
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structurally different for different bacterial species, and the sensor which receives these small 
molecules as signals varies from one bacterial species to another bacterial species. Two 
examples of the different signals/AI-2 (S-THMF borate and R-THMF) received by different 
protein sensors LuxP (Vibrio harveyi) and LsrB (Salmonella typhimurium) are shown in 
Figure 1.2.6  
 
 
Fig. 1.2 | Sensors Bound to Autoinducer-2 Signals. a. The sensor LuxP in Vibrio harveyi recognizes S-THMF-
borate as its AI-2 signal. b. The sensor LsrB in Salmonella typhimurium recognizes R-THMF as its AI-2 signal.6b, 
7The image is taken from a paper by Chen et al.6b 
 
1.2 |  S-Ribosylhomocysteinase (LuxS). The goal of this research project is to develop bio-
chemical assays capable of determining LuxS inhibition. LuxS is a 35 kDa homodimeric 
protein and is responsible for AI-2 biosynthesis (see Fig. 1.3).8 The active site of this protein 
lies between the two identical monomers.9 
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Fig. 1.3 | Crystal Structure of LuxS. The crystal structure of B.subtilis S-ribosylhomocysteinase containing 
cobalt in place of the native iron atom (Co-BsLuxS) in complex with a catalytic intermediate (depicted in ball and 
stick model) is shown. The ribbon diagrams of the two monomers are shown in two colors, purple and green. The 
image is taken from a paper by Rajan et al.10 
 
Initially, the metal ion in LuxS was proposed to be zinc (Zn2+). It was later speculated by Pei 
et al. that due to the similarity of the environment surrounding the metal ion (i.e. presence of 
two histidines, a cysteine and water at the metal binding site) to another Fe2+ containing 
enzyme, peptide deformylase, the native metal ion could be Fe2+.8a, 11, 12 In order to test the 
identity of the metal present in LuxS, three LuxS variants containing metals Fe, Zn and Co 
were prepared by Pei and coworkers (see Table 1.2).9 Based on the metal analyses and 
determination of catalytic activity, the native metal was Fe2+ in LuxS.9 Due to the easy 
oxidation the Fe2+ ion under the aerobic conditions of enzyme purification, the iron ion is 
routinely replaced to cobalt by addition of cobalt chloride in the culture when bacterial cells 
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are in their exponential growth phase.9 Pei and coworkers showed that the replacement of 
iron by cobalt in LuxS minimally affected the activity of the enzyme, yet facilitated its 
purification.9 The catalytic activity of the three LuxS enzyme variants with iron, zinc, or 
cobalt is summarized in Table 1.2. The catalytic parameters compared were: (1) KM: the 
binding affinity of substrate for the enzyme, (2) kcat: the number of substrate molecules 
converted to product per unit time and (3) kcat/KM : the catalytic efficiency of the enzyme. As 
shown, the catalytic parameters of the two enzymes (i.e. Fe-LuxS-HT and Co-LuxS-HT) 
were comparable. The replacement of iron by cobalt did not bring any significant change in 
the enzyme’s binding affinity (KM), as well as the kcat and catalytic efficiency (kcat/KM) values 
increased only by approximately two fold (see Table 1.2). Whereas the replacement of iron 
by zinc increased the value of KM by approximately thirty fold and the value of kcat by approx. 
four fold in comparison to the native iron containing LuxS (Fe-LuxS-HT). This led to 
decrease in overall catalytic efficieny (kcat/KM) of the enzyme (Zn-LuxS-HT) by nine fold 
(see Table 1.2). 
 
Table 1.2 | Comparison of Catalytic Activity of LuxS Variants. The catalytic activities of LuxS enzymes with 
different metal ions present at the active sites are compared. The table is taken from a paper by Pei et al.9 
Enzyme KM (µM) kcat (s-1) kcat/KM (M-1s-1) 
Fe-LuxS-HT 1.9 ± 0.2 0.018 ± 0.003 0.9 X 104 
Co-LuxS-HT 2.3 ± 0.5 0.035 ± 0.003 1.6  X 104 
Zn-LuxS-HT 58 ± 7 0.065 ± 0.008 0.1 X 104 
 
The mechanism of biosynthesis of AI-2 from S-ribosyl homocysteine (SRH) in the presence 
of LuxS was first elucidated by Pei and coworkers.9-10, 13 Figure 1.4 depicts substrate SRH, a 
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product of S-adenosyl homocysteine (SAH) (2) detoxification, where SAH is a byproduct of 
the numerous cellular methyl transfer reactions involving S-adenosyl methionine (SAM) (1). 
SAH is capable of inhibiting methyltransferases by competitive enzyme inhibition due to its 
structural similarity to SAM. Therefore, it is toxic to the cells and must be detoxified. In 
bacteria, SAH detoxification is done in two steps.4, 14 First, the nucleosidase Pfs acts on SAH 
to give S-ribosyl homocysteine (SRH) (4) after removal of adenosine (3). In the second step, 
LuxS acts on SRH to produce 4(S),5-dihydroxy-2,3-pentanedione (DPD) (5) and 
homocysteine (HCys) (6). In eukaryotes, LuxS is absent.15 Therefore, this detoxification is 
accomplished in one step by another enzyme, SAH hydrolase (SahH), with adenosine and 
homocysteine as the end products.13a, 15-16  
 
Fig. 1.4 | Biosynthetic Pathway of DPD (5). SAM (1) is converted to SAH (2) in presence of methyltransferases. 
Nucleosidase Pfs acts on SAH (2) to convert it into SRH (4) by removing adenosine. LuxS acts on SRH to convert 
it into homocysteine (6) and DPD (5). In eukaryotic cells SAH is detoxified by the action of SAH hydrolases, 
breaking SAH into adenosine and homocysteine (6). Methionine synthases acts on homocysteine to form 
methionine (7) which is converted to SAM (1) in presence of SAM synthetase.5bThe image is taken from the paper 
by lowery et al. 14 
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DPD forms the interspecies quorum sensing signal AI-2 upon cyclization.17 The structure of 
AI-2 may vary from species to species and two examples of different AI-2 signals formed 
from DPD cyclization i.e. Salmonella typhimurium and Vibrio harveyi are given in Fig. 
1.5.2,14,18 DPD is a very unstable molecule and it polymerizes upon concentration, making it 
difficult to isolate from biological samples.19 
 
 
Fig. 1.5 | AI-2 Structures. S-THMF borate acts as AI-2 signal for Vibrio harveyi whereas R-THMF borate acts as 
AI-2 signal for Salmonella typhimurium.5 
 
1.3 | LuxS Inhibition.  Quorum sensing inhibition prevents virulence in some bacterial 
species. For example, quorum sensing deficient strains of pathogenic Pseudomonas 
aeruginosa were unable to kill nematodes and amoebas.21 Eukaryotes were found to use 
natural anti-quorum sensing strategies to fight against harmful bacteria via an increase in pH 
and the secretion of small quorum sensing inhibitor molecules such as halogenated furanones, 
patulin and penicillic acid (see Fig 1.6).20 These natural defense mechanisms of eukaryotes 
against bacterial infections provided inspiration for the idea of interfering with the quorum 
sensing systems of pathogenic bacteria for the prevention of bacterial infections in humans 
using small molecules. 
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                           (A)                                     (B)                                   (C) 
Fig. 1.6 | Quorum Sensing Inhibitors Found in Nature. (A) Halogenated furanones are secreted by the marine 
alga Delisea pulchra. (B) patulin and (C) penicillic acid are secreted by fungi to inhibit quorum sensing in 
Pseudomonas aeruginosa. The images are taken from the paper by Givskov et al. and Rasmussen et al. 20b,20c 
 
The virulence inhibition by bacteria utilizing System Two quorum sensing is envisioned by 
inhibiting LuxS. The luxS gene has been identified in over 70 species, mostly utilizing 
quorum sensing for virulence expression (see Table 1.1), and makes LuxS a very attractive 
target.14 The inhibition of LuxS would inhibit AI-2 biosynthesis and, therefore, interspecies 
quorum sensing. One of the benefits of targeting LuxS is that it is absent in humans, allowing 
novel drugs to be designed that would inhibit LuxS and would likely be minimally toxic. In 
order to evaluate potential LuxS inhibition, the IC50 value of the inhibitor must be 
determined, which is the concentration of inhibitor needed to inhibit half of the maximum 
activity of LuxS through Ellman’s assay. Research directed at accomplishing LuxS inhibition 
by small molecules, both in vitro and in vivo include a competitive LuxS inhibitor as in 
Figure 1.7. This rationally-designed molecule gave a half maximal inhibitory concentration 
(IC50) value of 4.7 ± 1.7 µM against LuxS in vitro.21 
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Fig. 1.7 | Example of a Competitive LuxS Inhibitor. (S)-2-amino-4-((2S, 3R)-2,3-dihydroxy-4-(hydroxyamino)-
4-oxybutylthio)butanoic acid is shown to inhibit LuxS with an IC50 value of  4.7 ± 1.7 µM.21 The image is taken 
from a paper by Shen et al. 21 
 
Organic chemists in our lab are working towards synthesizing a new class of LuxS inhibitors. 
These inhibitors are designed to inhibit LuxS by inhibiting its dimerization of LuxS. 
Dimerization inhibitors like these have been reported previously for other enzymes.22 One 
example of a small molecule dimerization inhibitor is TSAO-T ([2’,5’-bis-O-(tert-
butyldimethylsilyl)-β-D-ribofuranosyl]-3’-spiro-5’’-[4’’-amino-1’’,2’’-oxathiole-2’’,2’’-
dioxide]), the first inhibitor to inhibit dimerization of HIV-1 reverse transcriptase enzyme.22a 
(Figure 1.8) This is a key enzyme and plays a vital role in the life cycle of the virus 
(responsible for HIV). Therefore, it is a target for antiviral intervention.22a   
 
Fig. 1.8 | Example of Small Molecule Dimerization Inhibitor. TSAO-T (([2’,5’-bis-O-(tert-butyldimethylsilyl)-
β-D-ribofuranosyl]-3’-spiro-5’’-[4’’-amino-1’’,2’’-oxathiole-2’’,2’’-dioxide]) interferes with the dimerization of 
HIV-1 reverse transcriptase. The image is taken from the paper by Camarasa et al.22a  
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The enzyme HIV-1 reverse transcriptase (HIV-1 RT) is a heterodimer.22b His-tagged p51 and 
Flag-tagged p66 protein subunits for this enzyme were prepared and purified using Flag/His 
columns.22b The HIV-1 reverse transcriptase assay was used to assay dimerization inhibition 
of HIV-1 reverse transcriptase enzyme by TSAO-T through determination of IC50 values. In 
this assay an anti-FLAG detector antibody conjugated with e-tag was added to the Flag/His-
tagged p66/p51 HIV-1 RT.22b (see Figure 1.9) In dimeric state this e-tag is released which in 
turn releases methylene blue, which is detected to determine potential dimerization inhibition 
in presence of an inhibitor as in this case TSAO-T.22b Dimerization inhibition of this enzyme 
by a TSAO-T molecule inhibits the essential role played by this enzyme in the virus, 
demonstrating its therapeutic use. Before performing the real assay, docking studies were also 
performed using PyMol to test the TSAO-T as potential inhibitor.  
 
 
Fig. 1.9 | HIV-1 Reverse Transcriptase Assay. Anti-Flag detector antibody conjugated with e-tag is added to the 
His/Flag-tagged p66/p51 HIV-1 reverse trancriptase. The image is taken from the paper by Camarasa et al.22b 
 
The use of dimerization inhibitors for LuxS is something that has not been attempted before. 
The introduction of steric bulk at the homocysteine C3 and/or C4 positions of SRH is 
expected to inhibit LuxS dimerization by imposing the steric bulk at the active site (see Fig. 
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1.10). The inability of LuxS to dimerize properly could inhibit AI-2 production and therefore 
interspecies quorum sensing. 
 
 
Fig. 1.10 | Proposed LuxS Dimerization Inhibitors. Introduction of a steric bulk at the HCys C3 and/or C4 
positions of SRH is expected to interfere with LuxS dimerization, thereby inhibiting LuxS and interspecies 
quorum sensing. 
 
The project goal is to evaluate such SRH analogs as potential LuxS inhibitors by two 
biochemical assays: (1) Ellman’s assay, and (2) fluorescence proximity assay.   
 
1.4 | Ellman’s Assay. Ellman’s assay is the measurement of protein sulfhydryls in presence 
of 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) at a wavelength of 412 nm (see Fig. 1.11).24 It 
used as a biochemical assay for the assessment of putative SRH analogs as LuxS inhibitors.9, 
23 For example, it was used for assessment of (S)-2-amino-4-((2S, 3R)-2,3-dihydroxy-4-
(hydroxyamino)-4-oxybutylthio) butanoic acid as potential competitive LuxS inhibitor (see 
Fig. 1.7). Homocysteine has thiol group (-SH), a byproduct of LuxS action on SRH, and 
reacts with DTNB and breaks the disulfide linkage, splitting DTNB into two halves (see Fig. 
1.11). One half of this DTNB joins with the thiol group of homocysteine to form a conjugate 
with a disulfide linkage. The other half, 2-nitro-5-thiobenzoate, is quantified by measuring 
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the absorbance of visible light at 412 nm. The quantification of 2-nitro-5-thiobenzoate 
indicates the presence of homocysteine and therefore of DPD in the reaction mixture, thus 
determining LuxS activity.  
 
Fig. 1.11 | Ellman’s Assay for Detection of LuxS Activity. SRH converts into DPD and homocysteine (HCys) in 
the presence of LuxS. Homocysteine reacts with DTNB to form a conjugate, whereas the remaining half of DTNB 
gives a yellow color to the reaction mixture which is measured at 412 nm. 
 
The presence of an SRH analog that inhibits LuxS (e.g. S-anhydroribosyl-L-homocysteine) in 
the reaction mixture should prevent the formation of homocysteine. Therefore, there will be 
only a minimal increase in absorbance at 412 nm with respect to blank as compared to the 
increase in absorbance in the presence of SRH alone (see Fig. 1.12). This difference in 
recorded absorbances enables an assessment of a potential SRH analog that would be able to 
inhibit LuxS and therefore interspecies quorum sensing. 
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Fig. 1.12 | Ellman’s Assay in the Presence of a LuxS Inhibitor. (A) Increase in absorbance at 412 nm is 
recorded in presence of SRH alone in the reaction mixture. (B) Minimal increase in absorbance at 412 nm is 
recorded in the presence of a potential LuxS inhibitor. Figure generated from raw data provided by Alfaro, et al. 25 
 
Ellman’s assay is a reliable assay, known to work for the evaluation of LuxS inhibitors. It is 
time efficient because the absorbance measurements are taken over only 204 seconds. This 
assay also enables the determination of the catalytic parameters of the enzyme, which could 
be compared with the other enzyme variants for comparison of their respective catalytic 
efficiencies. However, there are also some drawbacks to this assay. First, surface thiols on 
LuxS can react with Ellman’s reagent even in the absence of the substrate. Second, an active 
enzyme is required for this assay, but the iron containing enzyme LuxS turns inactive when 
purified in aerobic conditions due to oxidation of iron. Third, a high volume of the reaction 
mixture (1 mL) is required. To prepare a 1 mL reaction mixture requires 10 µL of the 40 µM 
purified enzyme and 30 µL of 680 µM purified SRH. Hence, a substantial amount of enzyme 
and substrate is consumed in this assay, each of which is acquired only after extensive effort. 
The final disadvantage of using this assay for the evaluation of LuxS inhibitors is the inability 
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to determine whether the inhibition was achieved by typical competitive or dimerization 
inhibition.  
 
Despite its drawbacks, the Ellman’s assay will be used to evaluate LuxS inhibitors because it 
is the standard assay in the field. The preparation of an active enzyme and a negative control 
for this assay as well as optimization of this assay in our lab conditions are presented in 
Chapter 3. 
 
1.5 | Fluorescence Proximity Assay. To overcome one of the drawbacks of the Ellman’s 
assay-determining the kind of inhibition by a particular inhibitor-a fluorescence proximity 
assay is envisioned for the evaluation of potential SRH analogs as dimerization inhibitors of 
LuxS. The disruption of dimerization of a dimeric protein is possible given an inhibitor that 
binds between two protein monomers. The dimerization disruption could be determined when 
artificial fluorophores are incorporated onto each monomer at appropriate positions (see Fig. 
1.13).26   
 
Fig. 1.13 | Fluoroscence Proximity Assay for LuxS. In the presence of SRH as substrate, a fluorophore-attached 
active LuxS variant would be present as a dimer. Whereas in the presence of a C-3/C-4 position SRH analog, the 
steric bulk present on the analog could impose hindrance in the dimerization, resulting in dimer disruption and 
therefore a change in proximity of the LuxS monomers. 
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Fluorescence proximity assays have literature precedents for other enzymes but not for 
LuxS.26 For example, this type of assay was developed for the enzyme HIV-1 protease. One 
of the key steps in the life cycle of a human immunodeficiency virus (HIV) is the proteolytic 
cleavage of the viral polyprotein gene products into active structural and replicative proteins. 
The viral enzyme HIV protease is responsible for these precursors, and its inactivation would 
produce immature and non-infectious viral particles. These findings initiated a chain of 
intense research to inhibit this enzyme by synthetic inhibitors.26 HIV-1 protease is a 
homodimer with each monomer contributing equally to the active site. The fluorescence 
proximity assay for HIV-1 protease was based on an HIV-1 expression assay using cyan and 
yellow fluorescent protein tagged monomers. Non-peptidyl small molecules including 
darunavir and experimental protease inhibitors were used as dimerization inhibitors for this 
enzyme (see Fig. 1.14). When the two HIV-1 protease monomers attached to CFP and YFP 
were in close proximity, a focused laser beam excitation of CFP resulted in rapid energy 
transfer to YFP and the fluorescence photons were emitted by YFP. In the presence of a 
dimerization inhibitor of HIV-1 protease, the average distance between CFP and YFP became 
larger, therefore the energy transfer rate decreased, and the fraction of photons emitted by 
YFP was lowered. The dimerization inhibition by these inhibitors was monitored and their 
IC50 (concentration of inhibitors required to inhibit viral replication by 50%) values were 
determined for the potential inhibitors.  
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Fig. 1.14 | Dimerization inhibitor for HIV-1 Protease. Darunavir was one of the dimerization inhibitors used for 
the inhibition of HIV-1 protease. The IC50 value recorded for this inhibitor was 0.0034 ± 0.0005 µM.26 The image 
is taken from the paper by Mitsuya, et al. 26 
 
In the case of LuxS, the presence of SRH in the reaction mixture would promote dimerization 
and therefore fluorophore proximity (see Fig. 1.13). For the evaluation of potential SRH 
analogs as dimerization inhibitors, change in fluorescence needs to be measured. When a 
C3/C4 position SRH analog binds to a fluorophore-attached LuxS variant, the steric bulk 
present on the inhibitor inhibits enzyme dimerization, and the resultant changed relationship 
between the two monomers of LuxS causes a change in fluorescence.  
 
The measured change in fluorescence with time would be correlated to LuxS dimerization 
inhibition. Work towards the successful generation of a LuxS variant for use in the proposed 
fluorescence proximity assay is discussed in Chapter 4. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 | Protein Purification. The requirements and the method for the purification of protein 
are discussed as follows: 
 
2.1.1 | Chemical Reagents. Cobalt chloride (CoCl2), sodium chloride (NaCl), ethanol, 
manganese chloride (MnCl2), borate (H3BO3), ammonium molybdate ((NH4)6Mo7O24), 
copper sulfate (CuSO4), hydrogen chloride (HCl), D-glucose, ammonium sulfate 
((NH4)2SO4), potassium phosphate dibasic (KH2PO4), and potassium phosphate monobasic 
(K2HPO4) were purchased from Sigma Aldrich.  
 
2.1.2 | Biochemical Reagents, Kits and Supplies. Casamino acids and LB agar were 
purchased from BioWorld. Site directed mutagenesis kit and BL21(DE3) competent cells 
were purchased from Agilent Technologies. Ampicillin sodium salt and vacuum filtrations 
(nylon membranes, sterile) systems were purchased from VWR. TALON® Resin was 
purchased from Clontech laboratories. GeneJET™ plasmid purification kit, PageBlue™ 
protein staining solution, Tris EDTA (TE) buffer, PageRuler™ plus prestained protein ladder, 
bovine serum albumin (BSA) standard  kit, Bradford dye,  1 kb DNA ladder and 100 bp DNA 
ladder were purchased from Fermentas.   
 
2.1.3 | Literature Procedure for Purification of Co-BsLuxS-HT. The procedure for the 
purification of Co-BsLuxS-HT was reported in the paper by Pei et al. 9 
 
2.1.4 | Preparation of Reagents. The reagents required for the purification procedure were 
prepared as follows: (a)  Co-BsLuxS-HT Minimal Media (1 L). First, 1000 X trace metals 
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solution was prepared by adding 500 mM MgSO4, 0.5 mM NaCl, 0.1 mM MnCl2, 0.5 mM 
H3BO3, 1 µM (NH4)6Mo7O24 and 10 µM CuSO4 in 10 mL of 0.1 M HCl. Solution was then 
filtered through a stericup. 100 X sugar stock solution was prepared by adding 25% D-
glucose, 200 µg/mL thiamin, 100 µg/mL D-biotin and 10% (NH4)2SO4 in 500 mL of hot 
distilled water.  Solution was then filtered through a Stericup. Finally, for 1 L LuxS minimal 
media, 5.5 g KH2PO4, 10.8 g K2HPO4, 10 g NaCl and 5 g casamino acids were mixed into 
989 mL distilled water. 1 mL of 1000X trace metals stock solution was added to the solution. 
10 mL of 100 X sugar stock solution was added to the solution. The media was then filtered 
through a stericup with 0.45 µM pore size. (b) LB Amp75 Media (1 L). To 800 mL H2O was 
added the following: 10 g bacto-tryptone, 5 g yeast extract, 10 g NaCl. The pH was adjusted 
to 7.5 with NaOH and the volume was adjusted to 1 L with distilled water. The media was 
then autoclaved for 15 min. at 121°C. After media cools, add 750uL of 100mg/mL ampicillin. 
(c) 100 mM CoCl2 (50 mL). To 0.65 g of CoCl2 50 mL distilled water was added and then 
stored for future use at room temperature. (d) 100 mM Isopropyl β-D-1-
thiogalactopyranoside/IPTG (50 mL). IPTG was weighed 1.19 g and added to 50 mL of 
distilled water and mixed on a magnetic stirrer. 1 mL aliquots were prepared and kept in the 
freezer at -80°C for future use. (e) Preparation of the Freezer Stocks. To prepare freezer 
stocks 750 µL of the bacterial cultures grown in LB Amp75 media were added to 250 µL of 
80% glycerol in a 1.5 mL Eppendorf tube and stored in freezer at -80oC. (f) Buffers.  For 
preparation of mechanical lysis buffer a solution of 20 mM Tris·HCl (pH 8.0), 400 mM 
NaCl, 5 mM imidazole (pH 8.0) was prepared. To prepare chemical lysis buffer a solution  
with 20 mM Tris·HCl (pH 8.0), 0.5 M NaCl, 5 mM imidazole, 1% Triton X-100, 0.5% 
protamine sulfate, 20 µg/mL trypsin inhibitor, 50 µg/mL p-methylbenzenesulfonyl fluoride, 
and 70 µg/mL chicken egg white lysozyme was prepared. The Elution Buffer was made 
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consisting of 20 mM Tris·HCl (pH 8.0), 400 mM NaCl, 60 mM imidazole (pH 8.0). For the 
preparation of 10X running buffer, 30.3 g of trizma base, 144.0 g of glycine, 10 g of SDS was 
added to 1000 mL of distilled water and stirred into a homogenous mixture. (g) Preparation 
of 12.5% SDS-PAGE Gels. To make a 12.5% gel, a stacking gel solution and a separating gel 
solution were made. For preparation of the separating gel solution, 3.35 mL of distilled water, 
2.5 mL of 1.5 M Tris·HCl (pH 8.8), 55 µL of 20% SDS, 4 mL of Acrylamide/Bis, 80 µL of 
10% ammonium per sulfate (APS) were added. 8 µL of tetramethylethylenediamine 
(TEMED) was added last. For the stacking gel solution, 6.1 mL of distilled water, 2.5 mL of 
0.5 M Tris·HCl (pH 6.8), 55 µL of 20% SDS, 1.3 mL of 30% Acrylamide/Bis, 80 µL of 10% 
APS were added. 8 µL of TEMED was added last. Bio-Rad Mini-PROTEAN® Tetra 
handcast gel frame for two gels was set up.  First the separating gel solution was poured up to 
3/4th height of the gel frame and allowed to solidify. Isopropanol was immediately added to 
level the surface of the gel. After the gel was set (as could be seen from the leftover solution) 
isopropanol was removed by soaking into paper towels. The stacking gel was then added into 
the remaining space and combs were placed at the top of the gel frame. Once the gel has 
solidified, it was stored in the refrigerator by wrapping it in wet paper towels and parafilm. 
 
2.1.5 | Co-BsLuxS-HT Purification. A 5 mL LB Amp75 media containing the desired 
bacterial cells (ELS 1409 with Co-BsLuxS-HT cells) was grown for 16 hours at 37°C. 5 mL 
culture was then backdiluted to 50 mL Co-BsLuxS-HT minimal media Amp75 in a ratio of 
1:1000 and grown for 16 hours at 37°C. 50 mL culture was then backdiluted to 2 L of Co-
BsLuxS-HT minimal media Amp75 in a ratio of 1:50. The 2 L culture was then grown to an 
OD600~0.6 at 37°C. 1 mL of the media was saved as blank for the measurement of O.D. of the 
culture. 500 µL of the 100 mM CoCl2 stock was then added and the culture was incubated for 
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30 min. at 30°C. After 30 min, 250 µL of 100 mM IPTG was added. The culture was 
incubated for 16 hours at 30°C. After 16 hours the culture was centrifuged at 5000 rpm 
keeping the temperature of the centrifuge at 4°C to get a big pellet. The pellet was 
resuspended in 35 mL mechanical lysis buffer. The resuspended cells were lysed by French 
press at approximately 20,000 psi and then centrifuged to get a supernatant containing the 
Co-BsLuxS-HT protein. To purify the protein, supernatant was passed through TALON® 
cobalt resin column. The column was previously washed with 10 mL each of distilled water 
and mechanical lysis buffer. After passing the supernatant through the cobalt resin column, 
the column is then washed with 35 mL mechanical lysis buffer.  The 40 mL of elution buffer 
was added to the column to elute the desired protein. Then 40 blue fractions of 1 mL purified 
protein were obtained containing the desired protein in elution buffer. Later 40 mL of purified 
protein was concentrated using YM-10 centriprep tubes to a dark purple solution by 
centrifugation at temperature 4ºC and at a speed of 5000 rpm for approximately 2 to 3 hours. 
The purified protein was then mixed with 80% glycerol (30-33% of the entire volume) and 
frozen at -80°C for future use in activity assays.  
 
2.1.6 | Measurement of Protein Concentration by Bradford Dye Assay. For measuring 
protein concentration by Bradford dye assay, absorbance values for the bovine serum albumin 
(BSA) standards were measured in triplicate to obtain a standard curve. The volume and 
concentrations of BSA standards used were as given in Table 2.1 below. Transparent 96 well 
plates with transparent bottoms were used for the assay, which were bought from Costar (part 
no. 3598). A volume of 300 µL of Bradford dye was added to each well and absorbance 
values at 595 nm are measured after a delay of 8 min using EnVision® multlilabel reader. A 
delay of 8.0 min gives stable color change whose absorbance could be recorded at 595 nm.   
  
 
21
Table 2.1 | Bradford dye assay.  The concentration and volumes of BSA standards to be added for the standard 
curve are shown in the table above. 
 
The dilutions 1:10, 1:20, 1:40, 1:80 of the protein were prepared, and absorbance values were 
measured at 595 nm along with undiluted protein in triplicate. After recording the absorbance 
values in triplicate a curve was made using the averaged absorbance values of the BSA 
standards (corrected from blank absorbance value). The curve gave a linear equation, which 
was used for the calculation of the protein concentration for absorbance values falling inside 
the standard curve. 
 
2.1.7 | SDS-PAGE Gel. To run a SDS-PAGE gel a 5 mL pellet of the bacterial cells 
(acquired during centrifugation of 2 L culture) was resuspended in 1 mL of chemical lysis 
buffer by pipetting up and down gently. Before sonication, 500 µL of the resuspended cells 
were saved as the whole cell (WC) samples. Cells were then lysed by sonication in Eppendorf 
tubes for 5 min at 4°C. 250 µL of the cells lysed by sonication was then centrifuged at 8000 
rpm and at a temperature of 4ºC. Supernatant of the centrifuged sample was loaded on an 
SDS-PAGE. A volume of 12 µL of all three samples (i.e. whole cell (WC), sonicated (S) and 
sonicated as well as centrifuged (CS) samples) was added to 4 µL of the loading dye in PCR 
tubes. Samples were heated for 10 min at 95°C and loaded onto a 12.5% SDS-PAGE along 
BSA std. conc. 
mg/mL 
Volume of BSA std used 
( µL ) 
Amount of BSA 
( µg ) 
0 0 0 
0.125 4 0.5 
0.25 6 1 
0.25 4 1.5 
0.5 5 2 
0.5 4 2.5 
0.75 4.67 3 
0.75 4 3.5 
1 4 4 
  
 
22
with the ladder (L). The gel was run for ~45 min at 150 V and stained with ~30 mL of 
PageBlue protein staining solution (Fermentas) overnight on a belly dancer/shaker. Next day 
the gel was destained by 10% acetic acid solution until all the excess dye washes away. The 
gel was then viewed using the software Quantity One program (Bio-Rad) and a gel picture is 
acquired using a Bio-Rad Chemi Doc. 
 
2.2 | Negative Control Co-BsLuxS-HT C84A. The procedure for acquiring a negative 
control for the Ellman’s assay is discussed in the following sections:  
 
2.2.1 | Biochemical Reagents, Kits and Supplies. QuikChange® II XL Site-
Directed. Mutagenesis Kit, BL21(DE3) pLys competent cells were bought from Agilent 
Technologies Stratagene. LB agar and ampicillin sodium salts were purchased from VWR. 
GeneJET™ Plasmid Miniprep Kit was purchased from Fermentas. All designed primers were 
sent to Integrated DNA Technologies (IDT) for synthesis. Pellet Paint® Co-Precipitant was 
purchased from EMD4Biosciences, SOC medium from Sigma-Aldrich. 
 
2.2.2 | Preparation of LB Amp200 Media and Plates. For the preparation of plates 20 
grams of LB agar was added to 998 mL of distilled water, which was stirred and heated until 
boiling. 2 mL of 100 mg/mL ampicillin stock solution was added to 998 mL of LB agar 
solution. The solution was then spread throughout the sterile VWR® petridishes, once it has 
cooled to room temperature. The media added was then allowed to solidify at room 
temperature. The method for preparation of LB Amp75 Media is provided in Section 2.1.4.1. 
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2.2.3 | Site-Directed Mutagenesis. A wild type LuxS template was purified from a 5 mL LB 
Amp75 culture using GeneJET™ plasmid purification kit. C84A overlapping primers were 
designed using PrimerX software. These primers were sent to be created by IDT. 100 mM 
stock and 10 µM working solutions of these primers were made in distilled water. In a PCR 
tube 36 µL of distilled water, 2 µL of DNA template (10 ng/µL), 1 µL of forward and reverse 
primers, 4 µL of 10X reagent buffer, 2 µL of dNTP, 3 µL of quick solution and 1 µL of DNA 
polymerase were added. The reaction was run in a thermal cycler for site directed 
mutagenesis (SDM). The initial denaturation temperature for the parent DNA template used 
for SDM was 95ºC for 30 s. The cycling parameters set for 16 cycles of SDM were: (1) 
denaturation at 95ºC for 30 s (2) annealing at 55ºC for 1 min (3) elongation at 68ºC for 6 min 
for Co-BsLuxS-HT (1 min/kb).  
 
Pellet Paint® Co-Precipitant. PCR products were transferred to 1.5 mL capacity Eppendorf 
tube. To this, 50 µL of PCR product and 2 µL of the Pellet Paint was added along with 150 
µL of 95% ethanol. This reagent mixture was frozen at -80°C for one hour. After one hour 
this mixture was centrifuged at 14,000 rpm for 15 minutes. After 15 minutes the supernatant 
was discarded. A visible pink colored pellet was saved. 200 µL of 80% ethanol was added to 
the pellet, which was again centrifuged at 14,000 rpm for 10 minutes. After 10 min. the 
supernatant was again discarded and the pellet was dried using a Eppendorf vacufuge 
concentrator for ~1 hour. The dried pellet was resuspended in 20 µL of distilled water.  
 
Dpn-I Digestion and Transformation. To the resuspended pellet of the PCR amplified 
DNA, 2 µL of Dpn-I was added and loaded in thermal cycler for digestion at 37ºC for 2 
hours. After 2 hours of digestion, 2 µL of the digested product was added to 100 µL of 
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BL21(DE3) competent cells in a 15 mL BD falcon tube. This tube was incubated on ice for 
30 min. The cells were heat shocked at 42°C for 20 seconds. 900 µL of SOC medium was 
added to the tube containing the cells. The tube was incubated at 37°C for 1 hour. After one 
hour the transformed mixture was spread throughout the LB Amp200 plates. These plates were 
incubated at 37°C overnight.  
 
Plasmid Isolation and Sequencing. Next day colonies were picked and grown in 5 mL of 
LB Amp75 media at 37°C for 16 hours. After 16 hours 4.25 mL of culture was centrifuged to 
get a pellet, while 750 µL of added culture was used to make freezer stocks. The pellet was 
then used to purify the plasmid using the GeneJET™ Plasmid Miniprep Kit. Purified plasmid 
concentration was estimated using a Nanodrop spectrophotometer in ng/µL. This purified 
plasmid was then sent to either Seqwright or Sequetech for sequencing. The sequences 
received from Seqwright and Sequetech were then aligned against wild type LuxS sequence 
using Lasergene 8.0.  
 
2.2.4 | Co-BsLuxS-HT C84A Purification. Once the desired mutation was confirmed after 
aligning the mutated sequences against wild type Co-BsLuxS-HT sequences, the BL21DE3 
competent cells containing the desired Co-BsLuxS-HT mutant were purified using the 
purification method given in Section 2.1. The estimation of protein concentration by Bradford 
Dye Assay was performed as provided in section 2.1.6. 
 
2.3 | SRH Quantification. The SRH synthesized by the organic chemists in our laboratory 
(see Fig. 3.12) was quantified by fluorescamine quantification assay. The method for the 
assay is discussed in detail in the following sections: 
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2.3.1 | Chemical Reagents and Plates. Tyrosine, alanine, threonine, fluorescamine, and dry 
acetone were purchased from VWR. 96 well black plates with transparent, flat bottoms were 
purchased from Costar (part no. 3631). 
 
2.3.2 | Preparation of Reagents. The reagents required for the fluorescamine quantification 
method were (a) 55 mM Sodium Borate. The weighed amount of  2.097 g of sodium borate 
was added to 100 mL of distilled water, and the pH adjusted to 9.0 using 1 M HCl. (b) 
Tyrosine Standards (0–40 µM). Tyrosine standards of 0.5, 10, 15, 20, 25, 30, 35 and 40 µM 
were prepared in 55 mM of sodium borate (pH 9.0). (c) Fluorescamine Solution 1 mg/mL (10 
mL). Fluorescamine weighing 10 mg was added to 10 mL of dry acetone. (d) Known 
Standards. A stock solution of 20 mM was prepared for amino acids alanine and threonine in 
55 mM sodium borate solution (pH 9.0). (e) Preparation of 20 mM SRH Stock and ~1 mM 
SRH Working Solution. Based on the percentage yield (20%) of the final product of SRH 
synthesis the theoretical value of SRH determined was 0.09144 g in impure mixture 
(containing inorganic salts and water) of 0.9481 g. Dissolved the final product in 12 mL of 
distilled water to make a stock of 20 mM. For 1 mL of working solution dissolved 50 µL of 
20 mM in 950 µL of 55 mM sodium borate (pH 9.0).  
 
2.3.3 | Tyrosine Standard Curve. This assay was performed using Wallac EnVision™ 
multilabel reader. 125 µL of the tyrosine standards were added in triplicate to 96 well black 
plates with flat and transparent bottom. 62.5 µL of 1 mg/mL fluorescamine was then added to 
each well. The plate was shaken inside Wallac EnVision™ multilabel reader for 1 min. 
Emission values at 485 nm were recorded for all the tyrosine standards.  
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2.3.4 | Fluorescamine Quantification Assay. Several dilutions for the known and unknown 
samples were prepared in 55 mM sodium borate (pH 9.0). Known samples and unknown 
sample dilutions of 125 µL were then added to the wells in triplicate. A volume of 62.5 µL of 
1 mg/mL fluorescamine was added to the test solutions. After shaking for 1 min., emission 
values at 485 nm were recorded for all samples. A standard curve was plotted using all the 
emission values for the tyrosine standards. The linear equation of the standard curve was used 
to calculate the concentration values of known and unknown samples. The emission values 
measured for 1:20, 1:400 and 1:800 dilutions of SRH (~1 mM) working solution and 20 mM 
known samples (alanine & threonine) were within the range of tyrosine standards. Four 
replicates of fluorescamine quantification were performed. Percent error values were 
determined for the known samples in each round.  
 
2.4 | Ellman’s Assay. The requirement and procedure for performing Ellman’s assay is 
discussed below: 
 
2.4.1 | Chemical Reagents. Ellman's reagent (5,5'-dithiobis-(2-nitrobenzoic acid))/ DTNB, 4-
2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES) sodium salt, and NaCl were 
purchased from VWR. 
 
2.4.2 | Preparation of Reagents. To perform Ellman’s assay some reagents were required. 
The method for their preparations were: (a) 5X Co-BsLuxS-HT Buffer (50 mL). The 6.5 g of 
HEPES sodium salt (500 mM) were added to 50 mL of distilled water. The pH was adjusted 
to 7.0. Finally 2.1916 g of NaCl (750 mM) was added. (b) Co-BsLuxS-HT 40 µM (500 µL). 
The determined concentration of Co-BsLuxS-HT was 3.4 mM. A 100 µL volume of 5X LuxS 
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buffer and 6 µL Co-BsLuxS-HT stock were added to 394 µL of distilled water for a final 
concentration of 40 µM. (c) Co-BsLuxS-HT C84A 40 µM (500 µL). The determined 
concentration of the Co-BsLuxS-HT C84A was 2.8 mM. 100 µL of 5X LuxS buffer and 7 µL 
Co-BsLuxS-HT C84A stock were added to 393 µL of distilled water for a final concentration 
of 40 µM. (d) S-Ribosyl Homocysteine (SRH) 680 µM (1000 µL). A volume of 200 µL of 
5X LuxS buffer and 34 µL SRH stock (20 mM) were added to 766 µL of distilled water. (e) 
Ellman’s Reagent 15 mM (1 mL). 0.005 g DTNB was added to 1000 µL 5X LuxS buffer. (f) 
SRH Concentrations (0-68 µM). 68, 34, 17, 8.5, 4.25, 2.125 and 1.06 µM SRH solutions were 
diluted from a 20mM SRH stock solution in distilled water. 
 
2.4.3 | Homocysteine Assay. A Hewlett Packard B452A Diode Array Spectrophotometer 
was blanked using a reaction mixture containing 200 µL of 5X Co-BsLuxS-HT buffer, 790 
µL distilled water and 10 µL of 15 mM Ellman’s reagent. Homocysteine standards of 30 µL 
(0-68 µM) were added to a reaction mixture containing 200 µL 5X Co-BsLuxS-HT buffer 
and 760 µL distilled water.  A measured volume of 10 µL of the 15 mM Ellman’s reagent 
was added last to the cuvette. Absorbance values were measured at 412 nm. These 
absorbance values were plotted to obtain a standard curve. 
 
2.4.4 | Ellman’s Assay for Co-BsLuxS-HT. All the enzymes, SRH, buffers, distilled water 
and reagents were added together in the volumes and concentrations given in Table 2.2 
directly into 1 mL glass cuvette. 10 µL of the enzymes were added last. This was done so that 
the absorbance values were recorded from the beginning of the assay. Ellman’s assay for Co-
BsLuxS-HT was a kinetic assay. The absorbance readings at 412 nm were recorded every 17 
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seconds for 204 seconds. Diode array was first blanked with the blank mixture mentioned in 
Table 2.2.  
Table 2.2 | Ellman’s Assay. The concentrations, volumes of all the required reagents, buffers and enzymes to be 
added in a particular order are shown. 10 µL of the enzymes are added last to the cuvette and make sure there is no 
air bubble in the cuvette at any point while assaying. 
 
 
A Hewlett Packard B452A Diode Array Spectrophotometer was used for this kinetic assay, 
which was performed for 204 sec recording sample absorbance every 17 seconds. For 
calculating the initial reaction rates for Co-BsLuxS-HT and Co-BsLuxS-HT C84A (S3) 
Ellman’s assay was performed with varying SRH concentrations from 0-68 µM. The 
concentration of Co-BsLuxS-HT and Co-BsLuxS-HT C84A (S3) was kept constant at 40 
µM. The rest of the protocol was the same as Co-BsLuxS-HT test (see Table 2.2). Once the 
absorbance was measured at 412 nm it was used to determine the kinetic parameters KM and 
Vmax for the samples.  
 
Samples 5 X 
LuxS 
buffer 
(µL) 
Distille
d water  
(µL) 
Ellman’s 
reagent  
15 mM (µL) 
SRH  
680 µM 
(µL) 
Co-
BsLuxS-HT 
40 µM  
(µL) 
Co-BsLuxS-
HT C84A 
40 µM  
(µL) 
Blank 200 790 10 - - - 
Co-BsLuxS-
HT blank 
200 760 10 30 - - 
SRH blank 200 780 10 - 10 - 
Co-BsLuxS-
HT 
C84A blank 
200 780 10 - - 10 
Co-BsLuxS-
HT test 
200 750 10 30 10 - 
Co-BsLuxS-
HT C84A test 
200 750 10 30 - 10 
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2.4.5 | Estimation of Kinetic Parameters. Graph Pad Prism 5.0 was used for calculation of 
kinetic parameters using reaction rates (µmol/mg/min), which were derived from absorbance 
values recorded at 412 nm (see Fig. 3.18). The constant value of [E]t used for determining the 
kcat was 0.0008 µmole (see Section 3.4.2.2.1 and Fig. 3.18). The comparison of kinetic 
parameters of house-purified enzymes with the literature values were used for determining 
enzyme’s activity.9 
 
2.5 | Generation, Purification, Concentration Estimation and Activity Assay of Co-
BsLuxS-HT Mutants. The procedure for the generation, purification and activity assay of 
mutants generated from native cysteines is discussed as follows: 
 
2.5.1 | Biochemical Reagents, Kits and Supplies. NucleoSpin Gel and PCR clean up kit 
from E and K Scientific, Nde-I, Xho-I and Pst-I restriction enzymes from New England 
Biolabs, T4 DNA ligase from New England Biolabs, One step Ex Taq qRT-PCR Kit from 
TaKaRa, 1 kb DNA ladder, 100 bp DNA ladder and 5X loading dye from New England 
Biolabs, JM109 competent cells  from Qiagen. 
 
2.5.2 | Preparation of LB Amp200 Plates and LB Amp75 Media. The media and plates 
were prepared the same way as mentioned in Section 2.2.2. 
 
2.5.3 | Preparation of Agarose Gel. To prepare 1% agarose gel 1 g of agarose was added to 
100 mL of 0.5X Tris-Acetate-EDTA (TAE) buffer. The solution was heated, but not to the 
extent of boiling in order to avoid bubbles in the gel. The solution was cooled up to 60°C and 
then 1µL of ethidium bromide (10 mg/mL) was added and mixed thoroughly. For preparation 
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of running buffer for 1% agarose gel, 0.5X TAE was used was running buffer for the 1% 
agarose gel. To prepare 1000 mL of 0.5X TAE buffer from 100X TAE buffer, add 50 mL of 
100X TAE buffer in 950 mL of distilled water. 
 
2.5.4 | Site Directed Mutagenesis. Template plasmids were purified from 5 mL LB Amp75 
cultures using GeneJet™ plasmid purification kit. C22A, C41A and C126A overlapping 
primers were designed using PrimerX software as per the primer design protocol of the 
QuikChange® SDM kit (see Table 4.2). Non-overlapping primers were designed using 
PrimerSelect module of DNAStar Lasergene 8.0 (Table 4.5). The wild type Co-BsLuxS-HT 
sequence was used as a template for designing these primers. The primers were then ordered 
from IDT. The procedure for SDM was the same as mentioned in section 2.2.3. The 
procedures for using Pellet Paint® precipitant, Dpn-I digestion and transformation, plasmid 
isolation and sequencing were same as mentioned in Section 2.2.3. 
 
2.5.5 | Procedure for Cloning Technique for Obtaining Double Co-BsLuxS-HT Mutants. 
To start cloning, a purified pET-22b(+) vector was required. A wild type Co-BsLuxS-HT was 
lysed by GeneJET™ plasmid purification kit to obtain a purified plasmid. Five samples were 
prepared for the digestion (1) Blank: 15 µL distilled water, 2 µL of 10X NEB buffer 4, 2 µL 
of 100X BSA, 1 µL of Nde-I, 1 µL of Xho-I (2) Nde-I: 5 µL of purified plasmid from wild 
type Co-BsLuxS-HT, 11 µL of distilled water, 2 µL of 10X NEB buffer 4, 2 µL of 100X 
BSA, 1 µL of Nde-I (3) Xho-I: 5 µL of purified plasmid from wild type Co-BsLuxS-HT, 2 
µLof 10X NEB buffer 4, 11 µL of distilled water, 2 µL of 100X BSA, 1 µL of Xho-I (4) Pst-
I: 5 µL of the purified plasmid from wild type Co-BsLuxS-HT, 11 µL of distilled water, 2 µL 
of 10X NEB buffer 3, 2 µL of 100X BSA, 1 µL of Pst-I (5) Nde-I Xho-I: 5 µL of purified 
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plasmid from wild type Co-BsLuxS-HT, 11 µL of distilled water, 2 µL of 10X NEB buffer 4, 
2 µL of 100X BSA, 1 µL of Nde-I and Xho-I. All these samples were incubated for 1 hour at 
37°C. During incubation, a 1% agarose gel was prepared in 100 mL 0.5X TAE buffer (see 
Section 4.52.1). After 1 hour, 5 µL of 5X loading dye was added to all the samples and 
loaded onto the 1% agarose gel. After filling the gel tank with 0.5X TAE buffer, the gel was 
electrophoresed for 1 hour 45 min. at 100 V. A picture of the gel was taken using using 
Quantity One software and Bio Rad Chemi Doc. The band for pET-22b(+) vector was 
isolated by cutting from the gel using a sterilized blade and purified using NucleoSpin® gel 
clean up kit. The cleaned pET-22b(+) solution was saved at -80°C for future use. 
 
To obtain the DNA fragments encoding the double mutation C22AC84A (D5), primers were 
manually designed (see Table 3.4) and ordered from IDT for synthesis. 100 mM stock 
solutions and 10 µM working solutions of these primers were prepared. Two PCR reactions 
were performed : (1) 1 µL of Co-BsLuxS-HT C84A as template and 2 µL of the full length 
reverse and C22A forward primer (2) 1 µL of the Co-BsLuxS-HT C84A as template, 2 µL of 
the full length forward and C22A reverse primer. The 10X reaction buffers, dNTP’s and the 
Taq Polymerase enzymes were used from the Ex Taq PCR kit. A second round of PCR 
reaction was run using 1 µL of the abovementioned PCR reaction (1) and (2) as a template 
and 2 µL of the full length forward and reverse primers. PCR product of 50 µL from the 
second round of the PCR reaction was purified using the NucleoSpin PCR cleanup kit. Then 
15 µL of the 50 µL cleaned up reaction mixture was digested by the restriction enzymes Nde-
I and Xho-I for one hour and 30 min at 37°C. The digested mixture was purified again using 
NucleoSpin PCR clean up kit. The cleaned up PCR mixture of 15 µL was then ligated with 
the 50 µL of the clean pET-22b(+) vector with 2 µL of the T4 DNA Polymerase at 4°C 
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overnight along with a blank sample. The following day ligated mixture was kept at room 
temperature for 45 min. After 45min. the enzyme was inactivated by heating the ligated 
mixture at 70° for 10 min. Immediately after heat inactivation, the ligation mixture was 
placed on ice for 10 min. 2 µL of the ligated mixture wass then transformed into the JM109 
competent cells. This experiment was repeated 3 times; the other two times the competent 
cells used were XL-10 ultracompetent cells and BL21DE3 competent cells. After 
transformation, the mixture was spread onto LB Amp200 plates. The plates were incubated at 
37°C overnight. The next day, colonies were isolated and grown in 5 mL of LB Amp75 media. 
The plasmids encoding the mutation present in the bacterial cells in the culture were then 
purified using GeneJET™ plasmid purification kit. The concentration of the purified samples 
was measured using ND-1000 spectrophotometer and the samples were sent to Sequetech for 
sequencing. The samples received from the sequencing company were aligned using SeqMan 
Pro module of DNAStar Lasergene 8.0 to determine if they carry the desired mutation. 
 
2.5.6 | Purification of Co-BsLuxS-HT mutants Purification. Once the desired mutation 
was confirmed, the BL21(DE3) competent cells containing the desired LuxS mutant were 
purified using the purification method given in Section 2.1. 
 
2.5.7 | Estimation of Protein Concentration of Co-BsLuxS-HT Mutants by Bradford 
Dye Assay. See section 2.1.6. 
 
2.5.8 | Ellman’s Assay for Activity Assay of Co-BsLuxS-HT Mutants. The Ellman’s assay 
was performed similarly as mentioned in the Section above (see Section 2.4.4). 
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CHAPTER 3: ELLMAN’S ASSAY FOR LuxS 
ENZYMATIC ACTIVITY DETECTION  
 
 
Small molecules having structural similarity to the LuxS substrate, SRH, have the potential to 
act as LuxS inhibitors, thereby preventing System Two quorum sensing. In order to be able to 
determine whether or not an SRH analog acts as an inhibitor of LuxS, an Ellman’s assay was 
implemented in accordance with literature precedent.24 Ellman’s assay is a means of 
determining total sulfhydryl groups, including both protein-bound and free sulfhydryl groups, 
in biological samples using 5,5'-dithiobis-2-nitrobenzoic acid (DTNB; Ellman's reagent).24 
The assay is both stoichiometric and colorimetric, as one mole of thiol (-SH) substrate reacts 
with one mole of DTNB to release one mole of 2-nitro-5-thiobenzoate (NTB-) ion, which is 
quantified in a spectrophotometer by measuring the absorbance of visible light at 412 nm.24  
 
 
Fig. 3.1 | Ellman’s Assay. The substrate (R-SH) here represents a molecule with a free sulfhydryl group. The 
substrate reacts with DTNB to break the disulfide linkage in DTNB. One part of the broken DTNB joins with the 
substrate to give a conjugate whereas the other part, 2-nitro-5-thiobenzoate (NTB-) remains free in the solution 
and absorbs light at 412 nm. 
 
Before attempting to identify any SRH analogs as potential LuxS inhibitors, Ellman’s assay 
was first used to determine the activity of Bacillus subtillis LuxS enzyme with a cobalt ion in 
place of the native iron and a C-terminal histidine tag (Co-BsLuxS-HT). Chemically-
synthesized SRH prepared in our laboratory was used as a substrate.27  Co-BsLuxS-HT reacts 
with S-ribosyl homocysteine (SRH) to give 4(S),5-dihydroxy-2,3-pentanedione (DPD) as its 
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primary product and homocysteine as a byproduct (see Fig. 3.2). This homocysteine 
byproduct exhibits a free sulfhydryl group which can react with DTNB in the Ellman’s assay 
to give 2-nitro-5-thiobenzoate (NTB-). Absorbance of this ion at 412 nm indicates the 
presence of HCys in the reaction mixture and, therefore, the activity of Co-BsLuxS-HT.  
 
  
. 
Fig 3.2 | Ellman’s Assay for LuxS. Homocysteine (HCys) is formed from SRH in the presence of enzyme Co-
BsLuxS-HT. HCys then reacts with the DTNB to give the NTB- ion. 
 
There are three basic requirements for the Ellman’s assay: (1) quantified substrate, (2) 
purified enzyme, and (3) a negative control. Table 3.1 shows these basic requirements for an 
Ellman’s assay in general and the requirements for the assay of Co-BsLuxS-HT in particular. 
The acquirement of each, for assessment of Co-BsLuxS-HT is in particular described in the 
following sections. 
 
Table 3.1 | Ellman’s Assay Requirements. General and specific requirements for an Ellman’s assay. 
 
General Requirements Co-BsLuxS-HT Specific Requirements 
Purified protein Co-BsLuxS-HT 
Negative control Co-BsLuxS-HT C84A mutant 
Substrate at known concentration S-ribosyl homocysteine (SRH) 
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3.1 | Protein Purification.  The Co-BsLuxS-HT enzyme was purified from the Escherichia 
coli strain ELS1409.3 ELS1409 cells carry the expression vector pET-22b(+) containing a 
DNA insert coding for Bacillus subtillis LuxS as constructed by Pei and coworkers, from 
digestion of the vector by Xho-I and Nde-I.9 To facilitate the purification of this enzyme using 
cobalt resin, a ‘tag’ of six histidine residues is incorporated at the C-terminus of the DNA 
insert (see Fig. 3.3). The vector also contains an ampicillin resistance gene that provides a 
resistance property to the bacterial cells against the antibiotic ampicillin in growth media. 
This enables the selective growth of ELS1409 bacterial cells containing the plasmid encoding 
for Co-BsLuxS-HT. The vector pET-22b(+) carries a lacI gene that produces a repressor that 
binds to the operator to inactivate transcription. An inducer, if present in the culture media, 
binds with the repressor to stop it from inactivating transcription, leading to rapid production 
of desired protein. 
 
Fig. 3.3 | pET-22b(+) vector. The plasmid vector present in strain ELS1409 with (a) DNA insert encoding B. 
subtillis LuxS (b) Six histidine residues from 140-157 at the C-terminal end of the DNA insert (c) Ampicillin 
marker and (d) lacI  repressor gene. The image is taken from the paper by Lee et al. 26c 
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LuxS with its native iron atom is very unstable in vitro, oxidizing from the ferric to the 
ferrous state under aerobic conditions. In the Co-BsLuxS-HT variant, the native iron atom is 
replaced by cobalt atom. Cobalt is more stable at in vitro conditions, and the enzyme activity 
remains similar to that of the native enzyme.9 
 
3.1.1 | General Parameters for Co-BsLuxS-HT Purification. For the purification of Co-
BsLuxS-HT, the protein was overexpressed in a large culture of ELS1409 bacterial cells. The 
bacterial cells were lysed to acquire the protein. The bacterial lysate was centrifuged to obtain 
a supernatant containing the desired protein. The histidine-tagged protein was separated from 
cell debris and other proteins by affinity chromatography. The purified protein was 
concentrated and stored at -80°C by mixing the culture in the cryoprotectant glycerol. 
 
3.1.2 | Co-BsLuxS-HT Protein Overexpression and Cell Harvesting. A large (2 L) culture 
of Escherichia coli ELS1409 containing the desired Co-BsLuxS-HT protein was grown in 
LuxS Amp75 minimal media. The ampicillin present in the media facilitated selective growth 
of ELS1409 as mentioned previously (section 3.1). 
 
3.1.2.1 | Fresh Transformation Required for Acquiring Purified Co-BsLuxS-HT. 
According to standard procedure, a freezer stock of ELS1409 bacterial cells stored at -80°C 
for a long time is used to generate a new bacterial culture.9 However, this method was 
unsuccessful in our lab conditions. The long-term storage of ELS1409 was hypothesized to 
have caused the loss of the gene encoding for Co-BsLuxS-HT from the plasmid, leading to no 
Co-BsLuxS-HT expression in the cells. To ensure that the Co-BsLuxS-HT protein was 
expressed in the cells, a freshly transformed stock of ELS1409 (renamed as RG-f) was used. 
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A fresh transformation refers to the transfer of the plasmid encoding the desired protein into 
fresh bacterial cells. The use of freshly transformed ELS1409 ensured the presence of the 
vector harboring the appropriate gene for Co-BsLuxS-HT expression in the bacterial cells.  
 
3.1.2.2 | Introduction of Cobalt and Isopropyl-β-D-thio-galactoside (IPTG) Induction. 
The RG-f bacterial cell culture was grown to an optical density (O.D.) at 600 nm (O.D.600) of 
~0.6 at 37°C. The O.D. of a bacterial cell culture is the logarithmic ratio of the radiation 
incident upon the culture, to the radiation transmitted through the culture.28  To determine the 
optical density at mid log phase of bacterial growth (i.e. maximal bacterial growth), the O.D. 
at 600 nm was measured with Diode Array spectrophotometer until an O.D.600 of ~0.6 
bacterial cell growth was achieved. First 500 µL of a 100 mM solution of cobalt (II) chloride 
(CoCl2) was added to the culture to replace the native iron in the active site of the enzyme 
with cobalt. In the presence of cobalt, the enzyme was blue. Next 250 µL of a 100 mM 
solution of isopropyl-β-D-thio-galactoside (IPTG) was added to the culture to induce rapid 
production of Co-BsLuxS-HT. The IPTG acts as an inducer by attaching itself to the lac 
repressor produced from lacI (see Fig. 3.3). The lac repressor releases from the lac operator 
(lacO shown in Fig. 3.3), thereby allowing the rapid transcription of the Co-BsLuxS-HT 
gene. After incubation at 30°C for 16 hours, the bacterial culture was centrifuged at 5000 rpm 
and 4°C to acquire a large pellet of bacterial cells carrying the plasmid coding for Co-
BsLuxS-HT.  
 
3.1.3 | Cell Lysis. The 2 L pellet of bacterial cells carrying plasmids encoding Co-BsLuxS-
HT obtained from RG-f overexpression was lysed to acquire the desired protein. Before 
lysing the bacterial cells by any particular lysis technique, the pellet was resuspended in a 
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lysis buffer to obtain a homogenous solution of bacterial cells. There are two potential lysis 
methods: chemical lysis by sonication and mechanical lysis by French press. Both methods 
were compared for RG-f to determine the best method that lysed maximum number of cells to 
provide blue Co-BsLuxS-HT protein. Once the purified protein was acquired, the amount of 
protein concentration was measured by the Bradford dye assay (see Section 3.1.5). 
 
3.1.3.1 | Sonication. Pei et al. used a sonication method for lysis of ELS1409 bacterial cells.9 
Applied to our case, the bacterial cell lysis by sonication required a 1 L pellet of RG-f cells to 
be resuspended in 35 mL of a chemical lysis buffer containing 1% Triton X-100, 0.5% 
protamine sulfate, 20 µg/mL trypsin inhibitor, 50 µg/mL p-methylbenzenesulfonyl fluoride, 
and 70 µg/mL chicken egg white lysozyme. The resuspended solution was divided into four 
parts. Each part of the resuspended cells was sonicated individually for 10 min at amplitude 
75 at 4°C. After centrifugation, 1 mL of supernatant was plated on LB Amp200 plates to 
determine if the cells were lysed or not. As mentioned in Section 3.1, the ampicillin marker 
present in the plasmid carried by RG-f cells makes the cells resistant to ampicillin. Hence, the 
unlysed RG-f cells with the plasmid will grow on the plates, suggesting incomplete lysis. 
Therefore, the expected number of colonies after lysis and centrifugation was zero. However, 
the actual numbers of colonies obtained were ~300 informing incomplete lysis of the 
bacterial cells.  
 
The enzyme purified from cells lysed by sonication was dark yellow in color rather than blue 
(see Summary Table 3.2). This indicated loss of cobalt from Co-BsLuxS-HT during the lysis 
procedure. The amount of the protein present in purified LuxS was later determined by 
Bradford dye assay to be 3.75 µg (Section 3.1.5). A summary table comparing the two 
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techniques i.e. sonication and French press for LuxS purification is given below (see Table 
3.2). 
 
3.1.3.2 | French Press. For cell lysis by French press, a 2 L pellet of RG-f bacterial cells was 
resuspended in 35 mL of mechanical lysis buffer containing 20 mM Tris-HCl, 400 mM NaCl 
and 5 mM imidazole. The cells were lysed by French press at 20,000 psi. After 
centrifugation, 1 mL of supernatant was plated on LB Amp200 plates. The presence of colonies 
suggested incomplete lysis of RG-f bacterial cells carrying the plasmid with ampicillin 
marker as mentioned previously, therefore no colonies were expected to grow. However, the 
number of colonies obtained was innumerable (i.e. separate single colonies were not 
obtained) suggesting incomplete lysis of bacterial cells. The protein purified from French 
press-lysed bacterial cells was blue (see Summary Table 3.2) as expected, presumably due to 
presence of cobalt in the enzyme. The amount of protein present in purified LuxS, determined 
by Bradford dye assay was 3.45 µg.  
Table 3.2 | Summary Table. The comparison of the two lysis techniques with respect to different parameters. 
 
 
 
The recovery of blue enzyme from the bacterial cells lysis by French press compelled us to 
use French press for future lysis experiments, despite the drawbacks of high colony count and 
lower protein amount of purified protein. 
 
Lysis Technique Size of the 
Culture 
Colonies 
Obtained 
Color of 
Protein   
Amount of 
Protein  (µg) 
Sonication  1L ~300 Yellow 3.75 
French Press 2L Innumerable Blue 3.45 
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3.1.4 | Affinity Chromatography. To purify Co-BsLuxS-HT from the mixture of other 
proteins present in the supernatant obtained after centrifugation, immobilized metal affinity 
chromatography (IMAC) was performed.29 The TALON® resin is charged with cobalt and 
therefore histidine tagged Co-BsLuxS, expressed from the plasmid vector present in RG-f 
cells (see Section 3.1), binds with the TALON® cobalt resin facilitating the protein 
purification. The binding of His-tagged protein to the resin turns the color of the resin from 
pink to blue (see Fig. 3.4). After the centrifuged sample was applied to column, it was 
washed with an appropriate lysis buffer to remove any other cell debris non-specifically 
attached to the column, the Co-BsLuxS-HT was eluted using a buffer containing imidazole, 
NaCl and Tris-HCl.  
 
 
Fig. 3.4 | Affinity Chromatography for His-tagged Protein. The His-tagged protein (purple) from a mixture of 
proteins, binds specifically to the resin due to its affinity. The retained His-tagged protein delivers the column a 
purple color. The image is taken from a paper by March et al.29 
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The purified Co-BsLuxS-HT was concentrated to a dark purple solution using centriprep 
YM-10 tubes (MWCO 10 kDa), which retained Co-BsLuxS-HT while let other impurities 
along with water pass through the membrane. The purified protein mixture was immediately 
mixed with 80% glycerol to be stored for future use at -80°C. 
 
 
 
Fig. 3.5 | Talon® Cobalt Resin Column. (A) Pink colored cobalt resin before the addition of supernatant. (B) 
The change of color from pink to purple of the cobalt resin column on passing the supernatant of cracked cells 
containing Co-BsLuxS-HT. 
 
3.1.5 | Bradford Dye Assay. The amount of protein present in the purified Co-BsLuxS-HT 
solution was measured by the Bradford dye assay to quantify the enzyme for the Ellman’s 
assay. The Bradford dye assay is a colorimetric protein assay based on an absorbance shift of 
the dye Coomassie brilliant blue G-250 (Fig. 3.6). Under acidic conditions, the red form of 
the dye is converted into its blue form to bind to the protein being assayed, resulting in a shift 
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of the dye’s absorption from the wavelength 465 nm to 595 nm.30 The binding of the protein 
stabilizes the blue form of the Coomassie dye. The amount of the complex present in solution 
was determined by an absorbance reading at 595 nm. The absorbance values of protein 
standards were plotted to obtain a standard curve, and the linear trendline equation of the 
standard curve was used to calculate the amount of the unknown protein samples.  
 
Fig. 3.6 | Bradford Dye Assay. The protein binds with the Coomassie dye to form a complex which is blue in 
color and the absorbance value is measured at 595 nm. The image is taken from a paper by Marion et al.31 
 
3.1.5.1 | General Parameters. Standard bovine serum albumin (BSA) solutions are mixed 
with an appropriate amount of Bradford dye. Once a stable color is acquired, the absorbance 
values are measured at 595 nm in a spectrophotometer. The absorbance values are plotted to 
obtain a standard curve and a linear trendline. The absorbance values for unknown samples 
are also acquired within the range of standard curve, using dilutions of the samples if 
required. The linear equation from the standard curve is used to calculate the amount of 
protein in the unknown sample.  
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3.1.5.2 | Optimization of Bradford Dye Assay for Co-BsLuxS-HT. Typically the Bradford 
assay is performed in large volumes (i.e. 1 mL). In an effort to avoid excess consumption of 
Co-BsLuxS-HT enzyme solely for quantification purposes, clear 96-well transparent bottom 
plates with a maximum working volume of 300 µL for each well were used.  Therefore, 
optimization of this low-volume Bradford dye assay was required beforehand. 4 µL of bovine 
serum albumin (BSA) standard solutions ranging from 0-2 mg/mL were used for 
optimization. To compare the determined unknown protein concentration results using a 
broad range of protein standards, BSA standards of concentrations 0-2 mg/mL were used. 
Different volumes of Bradford dye were also used ranging between 100 and 300 µL. The 
reaction mixture containing the BSA standards and the Bradford dye was kept at room 
temperature for 8 min in order to give a stable blue color from the protein-dye complex, 
which was then measured at 595 nm (see Section 3.1.5). The spectrophotometer used for 
absorbance measurements was Wallac EnVision™ multilabel plate reader (Perkin Elmer).  
The BSA standard range of 0-4 µg/mL and the 300 µL volume of Bradford dye provided a 
standard curve with a linear trendline and a R2 value of 0.96 (see Fig. 3.7).  
Bradford Dye Assay Standard Curve
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Fig. 3.7 | Bradford Standard Curve with Optimized Parameters. 0-4 µg/mL BSA standards and 300 µL 
volume of Bradford dye were used to acquire this standard curve with a linear trendline and small error bars. 
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3.1.5.3 | Protein Concentration Estimation of Unknown Sample. Once a standard curve 
was achieved, absorbance values for the unknown purified protein solution were determined. 
Serial dilutions of unknown purified Co-BsLuxS-HT samples in elution buffer (containing 20 
mM Tris-HCl, 400 mM NaCl and 60 mM imidazole) were prepared to achieve an absorbance 
within the range of absorbance values of standard curve (0-4 µg/mL). The linear equation of 
the standard curve was used to calculate the amount of protein present in unknown protein 
samples. The final protein concentrations of purified Co-BsLuxS-HT were determined using 
the amount of protein obtained from the linear equation. The protein concentration 
determined for the blue colored Co-BsLuxS-HT (bacterial cells lysed by French press) was 
0.49 mM and the concentration determined for the yellow colored Co-BsLuxS-HT (bacterial 
cells lysed by sonication) was 2.2 mM.  
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Fig. 3.8 | Bradford Assay Curve for Estimation of Amount of Protein in Purified Co-BsLuxS-HT Sample. 
The red dotted line in the curve shows the determined amount of protein present in 4 µL of 1:20 diluted Co-
BsLuxS-HT (lysed by French press), using absorbance measured at 595 nm. 
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3.1.6 | Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE). To 
check for the presence of Co-BsLuxS-HT protein in the chemically lysed bacterial cells 
before final purification of the enzyme, a SDS-PAGE gel was used. The technique of sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is used to separate proteins 
based on the differences in their molecular weights.26b The sodium dodecyl sulfate (SDS) 
used for SDS-PAGE is a strong detergent agent which denatures native proteins to unfolded, 
individual polypeptides. SDS imparts a uniform negative charge along the length of 
polypeptide giving every protein same mass to charge ratio, therefore the proteins separate 
based only on their respective molecular weights. The gel used for this technique is a 
polyacrylamide gel which is susceptible to high temperatures, transparent, strong and 
chemically unreactive. This gel helps to separate different proteins under appropriate voltage 
gradients.32 The description for the use of this technique for detection of Co-BsLuxS-HT 
presence, before attempting final purification, is provided in the following sections.  
 
3.1.6.1 | General Parameters of SDS-PAGE. SDS-PAGE gels of 12.5% are prepared. The 
protein samples to be tested are prepared by the addition of loading dye, followed by heating 
at 95°C for 10 min. The samples are loaded on the gel along with an appropriate protein 
ladder consisting of highly purified proteins of varying molecular weight. The electrophoresis 
was run at 150 V for ~45 min. The proteins separate on a SDS-PAGE gel according to their 
molecular weights and are visualized using a Coomassie Brilliant Blue protein stain. The 
molecular weight of the unknown proteins is estimated by comparing their bands with respect 
to the bands of the protein ladder.  
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3.1.6.2 | SDS-PAGE Gel for Co-BsLuxS-HT. The Co-BsLuxS-HT protein is a 35 kDa 
homodimeric protein (see Section 3.1). As SDS denatures proteins into monomers (Section 
3.1.6), the band for Co-BsLuxS-HT is expected at 17 kDa on the ladder. Whole cell (WC i.e. 
only resuspended), sonicated cells (RS i.e. resuspended then sonicated) and supernatant (S i.e. 
resuspended, sonicated and centrifuged) samples of Co-BsLuxS-HT were prepared are 
loaded. Multiple faint bands for different proteins were expected for WC sample because the 
sample was only resuspended in chemical lysis buffer. Therefore, only some of the cells were 
expected to be lysed due to presence of contents like lysozyme, salts etc. in the buffer. As 
well as for sample RS also multiple dark bands for different proteins were expected due to the 
maximum lysis of the cells by sonication and the presence of cell debris. The supernatant S 
was expected to give a dark band near 17 kDa band of the ladder, as all the cell debris was 
removed away and the supernatant was believed to have most of Co-BsLuxS-HT. A very 
faint band near 20 kDa was acquired for the WC sample. Dark bands near 20 kDa and 25 kDa 
bands of ladder were acquired for the RS sample. Until this time, the bands for Co-BsLuxS-
HT (S) around ~20 kDa band of the ladder have been acquired. (Fig 3.9) 
 
 
Fig. 3.9 | SDS-PAGE Gel. A faint band near 17 kDa band of ladder suggests the presence of Co-BsLuxS-HT.  
  
L Ladder 
WC Whole cell  
(resuspended) 
RS Resuspended  
(resuspended & lysed) 
S Supernatant  
(resuspended, lysed and 
centrifuged culture) 
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3.2 | Negative Control for Ellman’s Assay. A negative control is exactly the same as the test 
sample, but no phenomenon is expected according to the theory. The mutant Co-BsLuxS-HT 
C84A was used as a negative control for the Ellman’s assay. Based on the previous scientific 
work done on Co-BsLuxS-HT it is known that C84A mutation turns the enzyme inactive, as 
the cysteine 84 present at the active site of the enzyme plays a key role in the catalytic 
activity of the enzyme.9  
   
3.2.1 | General Parameters. To introduce a position-specific mutation in a protein, site 
directed mutagenesis is performed. Site-directed mutagenesis (SDM) is a technique used to 
create a mutation at a defined site in a DNA molecule using primers that encode for a 
particular mutation.33 After such primers are designed and prepared, a polymerase chain 
reaction (PCR) is run on a reaction mixture containing a DNA template, forward and reverse 
primers, reaction buffer, Quik solution (for dissolving all polar and non-polar compounds), 
deoxyribonucleotide triphosphates (dNTP’s), and a DNA polymerase enzyme. The final PCR 
product is then transformed into competent bacterial cells. The transformed cells are spread 
on an appropriate agar plate containing a particular antibiotic to ensure the selective growth 
of the cells carrying plasmids with antibiotic resistance. This plate is incubated at a 
temperature suitable for the bacterial growth overnight to grow colonies. Colonies are picked, 
grown in an appropriate media, and then lysed to purify the plasmid. Finally, these plasmids 
are sequenced and aligned to determine if the desired mutation was achieved. 
 
3.2.2 | Site Directed Mutagenesis for Co-BsLuxS-HT. The presence of a small side chain (-
CH3) in the neutral alanine made it a good choice for replacing cysteine at 84 position in 
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LuxS protein sequence according to Pei and coworkers.9 This change in the enzyme’s active 
site environment from cysteine to alanine turns the enzyme inactive.9  
 
1   MPSVESFELD    11  HNAVVAPYVR   21  HCGVHKVGTD     31  GVVNKFDIRF     41  CQPNKQAMKP  51 DTIHTLEHLL           Wild Type LuxS
61  AFTIRSHAEK      71 YDHFDIIDIS        81  PMGCQTGYYL     91 VVSGEPTSAE  101  IVDLLEDTMK    111 EAVEITEIPA           protein sequence
121  ANEKQCGQAK 131 LHDLEGAKRL  141  MRFWLSQDKE  151  ELLKVFG
CATTGATATTTCTCCAATGGGCGCGCAGACAGGCTATTATCTAGTTG                                          C84A forward primer
5’-ACGATCATTTTGATATCATTGATATTTCTCCAATGGGCTGCCAGACAGGCTATTATCTAGTTGTGAGCGGAGAGCCGAC-3’ Wild type LuxS
3’-TGCTAGTAAAACTATAGTAACTATAAAGAGGTTACCCGACGGTCTGTCCGATAATAGATCAACACTCGCCTCTCGGCTG-5’ DNA sequence
GTAACTATAAAGAAATTACCCGCGCGTCTGTCCGATAATAGATCAAC                                          C84A reverse primer
5’-ACGATCATTTTGATATCATTGATATTTCTCCAATGGGCGCGCAGACAGGCTATTATCTAGTTGTGAGCGGAGAGCCGAC-3’ Mutated LuxSC84A
3’-TGCTAGTAAAACTATAGTAACTATAAAGAGGTTACCCGCGCGTCTGTCCGATAATAGATCAACACTCGCCTCTCGGCTG-5’ DNA sequence
1   MPSVESFELD    11  HNAVVAPYVR   21  HCGVHKVGTD    31  GVVNKFDIRF     41  CQPNKQAMKP  51 DTIHTLEHLL             Mutated LuxSC84A
61   AFTIRSHAEK      71  YDHFDIIDIS       81  PMGAQTGYYL    91  VVSGEPTSAE  101  IVDLLEDTMK    111 EAVEITEIPA     protein sequence
121  ANEKQCGQAK  131 LHDLEGAKRL 141  MRFWLSQDKE  151  ELLKVFG  
Fig. 3.10 | Site Directed Mutagenesis. Stepwise depiction of Co-BsLuxS-HT C84A mutation generation.  
 
The primers encoding for the C84A mutation in Co-BsLuxS-HT have been designed and 
reported by Pei and coworkers (see Table 3.3).9 Different primers encoding for the same 
C84A mutation were designed in our lab using PrimerX (see Table 3.3), according to the 
primer design protocol of QuikChange site-directed mutagenesis kit by Stratagene. This 
protocol required primers of length 25-45 bases to have the mutation site in middle with ~10-
15 flanking bases. A Tm ≥ 78°C was required for DNA duplex stability and 40% GC content 
was needed to enhance the strength of the primers due to the presence of strongly bonded GC 
bases. Additionally, the primers were required to end with a G or C base, which helps to 
promote specific binding at the 3’ end. The primers designed in our lab were 10 bp longer 
than the Pei primers and the melting temperature was 5.5°C higher, but the GC content was 
almost identical (see Table 3.3). The desired sequences for the abovementioned C84A 
primers were sent to Integrated DNA Technologies (IDT) to be synthesized. SDM using the 
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QuikChange® site directed mutagenesis kit was used to mutate Co-BsLuxS-HT. PCR was 
performed using the wild type DNA template, C84A primers, buffers, deoxyribonucleotide 
triphosphates (dNTP’s) and PfuTurbo® DNA polymerase enzyme. Attempts to get colonies 
for Co-BsLuxS-HT C84A mutant using either pair of primers failed initially. It was 
hypothesized that the low concentration of the final PCR product was making it difficult for 
the bacterial cells to take up the plasmid during transformation, resulting in no colonies of the 
bacterial cells bearing the mutated plasmid. 
 
Table 3.3 | C84A Primers Comparison. The primers for C84A mutation of Co-LuxS-HT were designed by Pei 
and coworkers and also by our lab.9 The lengths and the parameters for designing the primers were different.  
Primer 
Design 
C84A Primers Length 
(bp) 
GC 
Content 
(%) 
Melting 
Temp. 
(°C) 
Pei et al 9 5’GATATTTCTCCAATGGGCGCCCA
AACAGGCTATTATC3’ 
 
37 45.95 74.1 
House-
designed 
5’CATTGATATTTCTCCAATGGGCGC
GCAGACAGGCTATTATCTAGTTG 3’ 
 
47 44.68 79.6 
 
3.2.2.1 | Pellet Paint® Co-Precipitant. To overcome the problem of low- concentration PCR 
product, Pellet Paint® Co-Precipitant was used to concentrate the PCR product from 50 to 20 
µL, thereby increasing the number of plasmids per unit volume available to the competent 
cells for uptake and leading to an increase in transformation efficiency (see Fig. 3.11). The 
number of colonies obtained for Co-BsLuxS-HT C84A mutation using the house-designed 
primers were 84. No colonies were acquired using Pei primers for the C84A mutation. Hence, 
Pellet Paint and the house-designed primers proved to be an important part of the protocol 
thereafter to acquire a mutant. 
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Fig. 3.11 | Procedure for Pellet Paint Paint® Co-Precipitant. To obtain higher number of colonies of bacterial 
cells carrying mutation the Pellet Paint Paint® Co-Precipitant was used for concentrating mutated DNA/PCR 
product. 
 
3.2.2.2 | Transformation. The concentrated PCR product was digested by the restriction 
enzyme Dpn-I to digest parent DNA and transformed into E. coli. BL21(DE3) competent 
cells by heat shock. The transformation mixture was spread on LB Amp200 plates for selective 
growth of cells with the ampicillin resistance plasmid. The colonies acquired were grown in 
LB Amp75 minimal media for selective growth (see Section 3.1). 
 
3.2.3 | Plasmid Isolation and Sequencing. The mutated plasmids from each bacterial culture 
grown in LB Amp75 minimal media were purified using Fermentas GeneJET™ Plasmid 
Purification Miniprep kit and the concentration of plasmid samples was estimated by UV-Vis. 
spectrophotometer (NanoDrop 1000). Plasmid samples of concentrations 100 ng/µL encoding 
for Co-BsLuxS-HT C84A were sent for sequencing to Seqwright. The alignment results 
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confirmed the presence of Co-BsLuxS-HT C84A encoding plasmids in the cells (see Fig. 
3.10).  
 
3.2.4 | Co-BsLuxS-HT C84A Purification. The bacterial cells containing mutated plasmid 
were grown and purified as mentioned in Section 3.1.  
 
3.2.5 | Estimation of Protein Concentration.  The amount of the protein was measured by 
Bradford dye assay as described in Section 3.1.5. The final concentration of blue-colored 
purified Co-BsLuxS-HT C84A protein determined was 1.1 mM (see Appendix A). 
 
3.3 | SRH Quantification. Ellman’s assay requires a known amount of substrate (SRH) in 
order to calculate the rate of reaction and kinetic parameters of the enzyme Co-BsLuxS-HT. 
Fig 3.12 shows the schematic presentation of the synthesis of SRH from homocysteine and 
protected ribose as initially attempted in our laboratory.9 The final product from this scheme 
is a mixture of inorganic salts (e.g. NaCl), SRH, and water. In order to quantify SRH in this 
mixture, there are two possibilities: (1) quantify SRH in solution or (2) synthesize SRH in a 
different way. The amount of SRH in the final product is quantified using fluorescence 
proximity assay, while efforts towards synthesizing more pure SRH were ongoing. 
 
 
Fig. 3.12 | Synthesis Scheme for SRH.  a. MsCl, Et3N, DCM, 0 °C –rt, Ar, 30 min; b. 1 M NaOH/H2O, 60 °C, 
Ar, overnight; c. TFA/H2O, 0 °C–rt, 3 hr.27 
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3.3.1 | Fluorescamine Quantification Assay. A fluorescamine quantification assay is a 
technique in which fluorescamine reacts with primary amines of amino acids to give 
fluorescent compounds. The fluorescence of these compounds is measured at an excitation of 
wavelength 390 nm and emission of wavelength 485 nm.34 SRH also has a free primary 
amino group which reacts with fluorescamine to give a fluorophore measurable at 485 nm 
(see Fig. 3.13).  
 
Fig. 3.13 | Fluorescamine Quantification of SRH. Fluorescamine reacts with three different amino acids tyrosine 
(pink), alanine (blue) and threonine (green). The fluorescamine reacts with SRH (red) in the same way due to the 
presence of a free amino group. Each of the reaction produces a fluorophore measured at 485 nm. 
 
3.3.2 | Tyrosine Standard Curve. The amino acid tyrosine is the standard for fluorescamine 
quantification assay in accordance with literature precedent.25 The results are demonstrated in 
Figure 3.14. The standard curve equation was used to calculate the amount of analyte in 
unknown samples. 
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3.3.3 | SRH Detection. To prepare the stock solution, a theoretical value of SRH was 
estimated from the overall yield of the chemical synthesis protocol (Fig 3.12) as 20%. The 
theoretical value of SRH is then 0.09144 g from 1 g of ribose, which was used to prepare “20 
mM” SRH stock in distilled water. One mM working solutions of SRH were prepared from 
this “20 mM” SRH stock in 55 mM sodium borate buffer.  
 
3.3.3.1 | Determination of Amount of SRH Present in the Mixture. Dilutions of SRH were 
made to obtain an emission values within the range of the tyrosine standard curve (0-40 µM) 
and were used to calculate the amount of SRH from the linear equation of the tyrosine 
standard curve (see Fig. 3.14 A). The concentrations of SRH determined from four replicates 
were 5.8, 4.4, 6.7 and 5.9 mM with a standard deviation of 0.96 (see Fig. 3.14 C), the values 
were four fold lower as compared to the original concentration of stock solution 20 mM of 
SRH. 
 
3.3.3.2 | Estimation of Known Samples of Alanine and Threonine. The absence of a SRH 
standard led us to use the amino acids alanine and threonine in the fluorescamine 
quantification assay to determine its accuracy (see Fig. 3.13). Working solutions for the 
amino acids alanine and threonine of concentration 20 mM were prepared in 55 mM sodium 
borate buffer and the assay was performed. Emission values were recorded, applied to the 
standard curve, and sample concentrations were determined (see Fig 3.14 B). The 
concentrations of amino acids determined in the known 20 mM alanine samples were 20.9, 
22, 39 and 35 mM with a standard deviation of 9.13 (see Figure 3.14 C). The percent errors 
for the alanine sample (of original conc. 20 mM) determined from four replicates were: 4.5, 
10, 95 and 75 % respectively. The concentration of amino acids determined in the known 20 
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mM threonine samples was 21.2, 30, 37 and 30 mM with the standard deviation of 6.47 (see 
Figure 3.14 C). The percent errors for the threonine sample of known concentration (20 mM) 
from four replicates were: 6, 50, 85 and 50 % respectively.  
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Fig. 3.14 | Tyrosine Fluorescamine Test. (A) The tyrosine standard curve and the linear equation was used to 
calculate the value of unknown SRH (red) sample. The red colored dotted line represents the amount of SRH 
determined using its emission value at 485 nm. (B) Determination of amount of alanine (blue) and threonine 
(green) used as known samples in one of the rounds from tyrosine standard curve. (C) Determined values of 
known alanine and threonine samples as well as unknown SRH samples in different replicates and their standard 
deviations are shown.  
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The high standard deviation values recorded for the known alanine and threonine samples 
from four replicates indicated imprecision in the method. And the high percent error values 
recorded for different replicates of fluorescamine quantification assay for the known amino 
acid standards (alanine and threonine) indicated inaccuracy. Hence, this assay was deemed to 
be unreliable (see Fig. 3.14). Therefore, a new synthesis scheme for SRH was devised and 
this new synthetic scheme provided more pure SRH without any further quantification.27, 35 
 
3.4 | Ellman’s Assay. As all of the required components of Ellman’s Assay were acquired, 
activity assay for Co-BsLuxS-HT was ready to be performed.  
 
3.4.1 | General Parameters. The assessment of the activity of an enzyme delivering an end 
product with a thiol group is done by an Ellman’s assay. An appropriate enzyme is mixed 
with its substrate in a reaction mixture and the –SH group of the product reacts with DTNB to 
break into two equal parts (see Fig. 3.1). One of the parts reacts with the thiol group of the 
product to generate a conjugate. The other part (NTB-) absorbs light at 412 nm (see Fig. 2.1). 
A time-dependent kinetic Ellman’s assay, with varying concentrations of substrate, is 
performed to acquire reaction rates. These reaction rates are used to plot a Michaelis-Menten 
curve and to determine kinetic parameters: the maximum enzyme velocity (Vmax), the 
substrate concentration at half Vmax (KM), and the turnover number (kcat).  
 
3.4.2 | Ellman’s Assay for the Enzyme Co-BsLuxS-HT. In an effort to optimize the 
protocol for Ellman’s assay, commercially-available homocysteine was used. As discussed 
previously, Ellman’s reagent detects homocysteine as an indirect determination of LuxS 
activity (see Fig. 3.2).  
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3.4.2.1 | Optimizing Ellman’s Assay by Homocysteine Quantification. According to the 
literature, an Ellman’s assay for LuxS activity utilizes 30 µL of 680 µM SRH with 10 µL of 
40 µM Co-BsLuxS-HT enzyme.9 If 0.0204 µmoles of SRH (determined from 30 µL of 680 
µM SRH) were completely converted to 0.0204 µmoles of homocysteine by the enzyme Co-
BsLuxS-HT, the concentration of homocysteine produced in 1 mL of the reaction mixture 
would be 20.4 µM. 
 
 
Fig. 3.15 | Homocysteine Quantification. Homocysteine reacts with 5,5'-dithiobis-(2-nitrobenzoic acid)/DTNB 
to give a disulfide conjugate and a yellow colored byproduct NTB-, which is measured at 412 nm. 
 
In order to be close to the maximum amount of homocysteine that could be produced in a true 
LuxS assay, homocysteine solutions of concentrations approximating 20.4 µM were 
prepared. Homocysteine solutions from 0-80 µM were reacted with Ellman’s reagent. Six 
replicates of the assay were performed. The absorbance values recorded in each round were 
averaged, and a standard curve was plotted using these values. The error was determined as 
standard deviation. Linear trendline resulted in an R2 value of 0.9996. Apart from optimizing 
this assay for the real Ellman’s assay, this procedure also indicated a maximum absorbance 
that could be acquired for the enzyme in 1 mL of reaction mixture. The maximum absorbance 
value that could be acquired from complete conversion of 0.0204 µmoles of SRH into 0.0204 
µmoles (7.8 µg) of homocysteine and DPD in a 1 mL reaction mixture was 0.840 (see Fig. 
3.16). 
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Fig. 3.16 | Homocysteine Assay.  The standard curve acquired after averaging the absorbance values from the six 
rounds of the homocysteine assay. The error bars indicate units of standard deviation. The red dotted lines show 
the maximum absorbance value that could be recorded for Co-BsLuxS-HT. 
 
3.4.2.2 | Co-BsLuxS-HT Assay.  After optimizing the Ellman’s assay, the activity assay for 
the enzyme Co-BsLuxS-HT was performed. A reaction mixture containing SRH, Ellman’s 
reagent, distilled water, 5X LuxS buffer and Co-BsLuxS-HT was prepared (see Table 2.2). 
The enzymes were added at last to the cuvette with reaction mixture to ensure that absorbance 
values are recorded from the beginning of the enzymatic reaction.  The absorbance values at 
412 nm were measured every 17 seconds for a total of 204 seconds. Similarly, an Ellman’s 
assay was performed for Co-BsLuxS-HT C84A, blank (with neither enzyme nor substrate), 
SRH blank (with only substrate and no enzyme), and enzyme blank (with no SRH and only 
enzyme). The absorbance values recorded under each set of conditions were plotted to obtain 
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a curve. The curves acquired for different samples were compared with each other to check 
the enzyme activity. Fig. 3.17 (A) shows the Co-BsLuxS-HT curve with increasing slope as 
compared to others depicting that the enzyme is binding with the substrate and producing 
homocysteine. The mutant Co-BsLuxS-HT C84A was found to be inactive (but with high 
background) as expected (see Section 3.2).9 
 
The activities of the Co-BsLuxS-HT enzyme and its mutant were also determined as fold rate 
enhancement over their enzyme blanks (in absence of substrate). The linear equations of the 
curves for enzymes and their respective blanks (in absence of substrate) provided the slope, 
which was used to calculate the fold rate enhancement for the enzymes Co-BsLuxS-HT and 
Co-BsLuxS-HT C84A (see Fig. 3.17 (B)). A 4.7 fold increase was observed in freshly 
purified Co-BsLuxS-HT activity from Co-BsLuxS-HT blank. On the other hand, a 0.2 fold 
increase was observed for the negative control Co-BsLuxS-HT C84A from its respective 
blank. The fold rate enhancement values demonstrated that Co-BsLuxS-HT purified in our 
lab conditions was active whereas C84A mutant was inactive. 
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Fig. 3.17 | Ellman’s Assay Curves & Fold Rate Enhancement. (A)The curves for different samples of Ellman’s 
assay obtained from the absorbance values recorded at 412 nm. A continuous increase in the absorbance values of 
blue solid trendline for Co-BsLuxS-HT which depicts the rapid formation of homocysteine by the action of Co-
BsLuxS-HT on SRH. (B) The fold rate increase in activity of enzyme over their respective blanks is depicted 
using values of slope acquired from three rounds of activity assay. 
 
3.4.2.2.1 | Kinetic Parameters of Co-BsLuxS-HT. For the comparison of the activity of Co-
BsLuxS-HT purified in our lab conditions with the Co-BsLuxS-HT purified by Pei et al., the 
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kinetic parameters Vmax, KM, kcat and catalytic efficiency of the enzyme were determined.9 
Vmax is the maximum enzyme velocity, whereas KM, the amount of substrate at half of Vmax, is 
used to evaluate the binding affinity of the enzyme. The kinetic constant kcat defines the 
turnover number of an enzyme, i.e. the number of substrate molecules converted to product 
per second. The ability of an enzyme to convert the substrate into product at a high reaction 
rate is called its catalytic efficiency. The kinetic parameters determined by us for the house-
purified Co-BsLuxS-HT were expected to be comparable with the published values by Pei et 
al.9 
 
The parameters KM and Vmax of Co-BsLuxS-HT were determined via an Ellman’s activity 
assay using variable concentrations of SRH.a The absorbance values (AU/s) of enzymatic 
reactions using 0-68 µM SRH according to the protocol set by Pei were recorded at 412 nm 
(see Table 2.2 for reaction composition).9 These values were then converted to reaction rates 
in units of µmol/mg/min for comparison to the reaction rates provided by Pei et al.9 The 
equations used for determining the amount of Co-BsLuxS-HT present in 1 mL of final 
reaction mixture and the conversion of units of reaction rates from AU/s to µmol/mg/min are 
provided in Fig 3.18 (A) & (B). A Michaelis-Menten curve was plotted using these values of 
reaction rates (µmol/mg/min) versus SRH concentration in Graph Pad Prism 5.0, to relate the 
rate of enzymatic reaction to the concentration of the substrate.23a,36 The Michaelis-Menten 
curve was used to determine the kinetic parameters KM (µM) and Vmax (µmol/mg/min) for 
                                                 
a Initially, to acquire reaction rates for plotting the Michaelis-Menten curve, SRH concentrations from 
0 µM-2000.0 µM were used (see Appendix B). The KM values determined for Co-BsLuxS-HT purified 
in our lab using the above mentioned SRH concentration range was 93.5 µM, which was 
approximately six fold higher than the KM value (i.e. 2.3 µM) of the Co-BsLuxS-HT reported by Pei et 
al.9 Later, an SRH concentration range of 0 µM to 68 µM, as used in the published paper by Pei et al. 
for calculation of kinetic parameters, was used for a revision of the calculation of kinetic parameters of 
Co-BsLuxS-HT enzyme purified in our lab conditions. 9 
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Co-BsLuxS-HT. The KM value of 2.1 µM was comparable to the KM value of 2.3 µM 
reported by Pei and coworkers (see Fig 3.19), indicating that the enzyme purified in our lab 
conditions binds equally well to the substrate.9 The enzyme’s maximal velocity (Vmax) in 
µmol/mg/min was converted to µmol/s using the equation (D) in Fig. 3.18. The Vmax for 
house-purified Co-BsLuxS-HT (1.1 x 10-5 µmol/s) was approximately 2.5 fold less as 
compared to the Vmax value (2.8 x 10-5 µmol/s) of Co-BsLuxS-HT provided by Pei et al., 
indicating that the time taken by the house-purified enzyme to convert one mole of substrate 
into product was 2.5 times greater.9  
 
To calculate the value of kcat, the concentration of enzyme active sites in a reaction mixture 
[E]t was required. The enzyme Co-BsLuxS-HT is a homodimer of molecular weight 34438 
g/mol with 2 active sites. Thus, the value of [E]t obtained according to equation (D) in Fig. 
3.18 was 0.0008 µmoles. The value of kcat for house-purified Co-BsLuxS-HT was 0.014 s-1 
(determined using the equation (E) in Fig. 3.18) which was 2.5 fold less than the value of kcat 
provided in literature (0.035 s-1). This value indicated that one mole of substrate took 2.5 fold 
greater time to be converted into product, which was expected according to the lower Vmax for 
the house-purified enzyme. The catalytic efficiency (determined using the equation (F) in Fig. 
3.18) of house-purified LuxS was 0.67 x 104 M-1/s-1, which was 2.4 fold lower than the 
catalytic efficiency (1.67 x 104 M-1/s-1) of the enzyme purified by Pei and coworkers. Again 
because the maximal reaction rate Vmax was lower than the literature values, it affected the 
catalytic efficiency of the enzyme.9 Although the value of KM was comparable, but the lower 
kcat, Vmax, and catalytic efficiency values of house-purified Co-BsLuxS-HT as compared to 
those provided by Pei et al., depicted some discrepancies in purification procedure of house-
purified Co-BsLuxS-HT. The KM value of the house-purified enzyme demonstrated that the 
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enzyme and substrate bind well but somehow the conversion of substrate to product was 
slow. One probability for this could be that the cysteine 84 amino acid residue, that initiates 
catalysis in the active site, gets oxidized to some extent during the slow manual protein 
purification process thus impairing the overall catalytic ability of the stock solution.
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(A) Determination of  amount of LuxS in cuvette (mg) 
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(C) Conversion of maximum reaction velocity (Vmax) units from µmol/mg/min to µmol/s 
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(E) Calculation of kcat         
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(F) Calculation of catalytic efficiency        
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Fig. 3.18 | Calculations and Unit Conversions for Determination of Kinetic Parameters of Co-BsLuxS-HT. The equations used for determination of LuxS (mg) (A), 
[E]t (D), kcat (E), catalytic efficiency for Co-BsLuxS-HT (F) and unit conversions of recorded absorbances at 412 nm (B) and Vmax  (C). Where no. of active sites in Co-
BsLuxS-HT is 2, molecular weight of Co-BsLuxS-HT is 34882 g/mol and molar absorption efficient coefficient for DNTB- (ε) is14150 M-1cm-1.  
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Enzyme KM             
(µM) 
Vmax 
(µmol/s) 
kcat  
(s-1) 
kcat / KM 
(M-1/ s-1) 
Co-Bs-LuxS-HT 
House-purified 
2.1 ± 1.4  1.1 x 10-5 0.014  ± 0.002  0.67 x 104 
Co-Bs-LuxS-HT 
(by Pei et al.)9 
2.3 ± 0.5 2.8 x 10-5 0.035± 0.003 1.6 X 104   
 
 
Fig 3.19 | Michaelis-Menten curve, Lineweaver Burk Plot and Comparison of Kinetic Parameters. (A) 
Michaelis-Menten curve for Co-BsLuxS-HT purified in our lab conditions with error bars depicting the 
absorbance values recorded in triplicate. The Michaelis-Menten curves for each individual round are provided in 
Appendix B. (B) Lineweaver Burk plot for calculation of kinetic parameters (C) Kinetic parameters of the two Co-
BsLuxS-HT enzymes.  
 
3.5 | Conclusion and Future Directions. The Ellman’s assay is ready to be used for 
determination of potential SRH analogs as inhibitors of the enzyme Co-BsLuxS-HT. Before 
determination of the activity of putative Co-BsLuxS-HT inhibitors, the Ellman’s assay was 
also used for activity assay of other Co-BsLuxS-HT mutants (See Chapter 4). This assay 
proved to be a useful tool to determine the activity of Co-BsLuxS-HT mutants which were 
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required for fluorescence proximity assay discussed in Chapter 4. In future this assay will be 
optimized for 96 well plate, for minimizing excessive use of enzymes and substrates.
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CHAPTER 4: FLUORESCENCE PROXIMITY ASSAY 
 
Several types of inhibitors of LuxS have been designed and tested in the literature, including 
SRH analogs modified at the ribosyl C3 position, analogs with a [4-aza] ribose ring and (S)-
2-amino-4-((2S, 3R)-2,3-dihydroxy-4-(hydroxyamino)-4-oxybutylthio) butanoic acid.21,23b,25,35 
The SRH analogs proposed by our lab are a new class of LuxS inhibitors, and are expected to 
inhibit LuxS by disrupting its dimerization (see Fig. 3.2). These analogs are structurally 
similar to SRH except an alkyl or aryl group will be introduced at the homocysteine C3 
position (see Fig. 4.1). This is expected to inhibit the Co-BsLuxS-HT enzyme monomers 
from dimerizing correctly, as has been previously reported for other enzymes.26  
 
SRH Homocysteine C3 analogs (R = alkyl or aryl) 
Fig. 4.1 | Proposed SRH Homocysteine C3 Analogs as LuxS Dimerization Inhibitors. The addition of bulky 
groups at the 3rd position of SRH is expected to disrupt LuxS dimerization. 27, 35 
 
As discussed earlier, the LuxS enzyme is a 35 kDa homodimeric protein. SRH positions itself 
at the active site, present in between the two monomers, and is catalytically converted to DPD 
and homocysteine (see Fig. 4.2). The DPD produced from SRH cyclizes to form the 
interspecies quorum sensing AI-2, which initiates System Two quorum sensing (see 
Introduction). The replacement of SRH by a potential dimerization inhibitor at the active site 
would inhibit DPD production and therefore AI-2. This results in an inhibition of quorum 
sensing and its related behavioral responses (virulence, etc.). 
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Fig. 4.2 | Co-BsLuxS-HT Binding Site. The binding site of Co-BsLuxS-HT C84A, with a catalytic 2-ketone 
intermediate (magenta) present at the position where SRH binds. One monomer is shown in yellow with names of 
the amino acid residues in red, and the other monomer is shown in green with the names of amino acid residues in 
blue. The structures of the major residues in the active site are enhanced (other residues are depicted by thin 
sticks).  
 
Fluorescence proximity assay would be used for the detection of dimerization inhibition of 
LuxS by the abovementioned dimerization inhibitors. A fluorescence proximity assay is a 
technique used to assess the inhibition of a dimeric protein in the presence of a potential 
dimerization inhibitor by measuring the change in fluorescence upon monomer separation.37 
Assays of this general type have been used previously for enzymes like DNA polymerase III 
and HIV protease (see section 1.5).26 
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Fig. 4.3 | Fluorescence Proximity Assay for Co-BsLuxS-HT. A fluorophore is attached to the Co-BsLuxS-HT 
active mutant. The fluorescence changes when a dimerization inhibitor comes in between the two monomers of 
homodimeric Co-BsLuxS-HT. This change in fluorescence could be measured over time for detection of 
dimerization inhibition. 
 
The fluorescence of a Co-BsLuxS-HT variant conjugated with a fluorophore remains 
unaltered when the protein is in its dimeric state (see Fig. 4.3). If a dimerization inhibitor 
comes in between the two monomers of the enzyme, the result is a change in proximity 
between the monomers, which leads to a change in fluorescence. The measurement of this 
change in fluorescence over time could help to detect the dimerization inhibition. To detect 
the inhibition of Co-BsLuxS-HT enzyme by potential inhibitors, there are two basic 
requirements: (1) a fluorophore-attached active Co-BsLuxS-HT mutant and (2) SRH analogs 
as potential dimerization inhibitors. The organic chemists in our laboratory are currently 
working towards synthesizing a SRH analog which could act as a dimerization 
inhibitor.18,35,38 In the meantime, experimental work towards acquiring a fluorophore-attached 
Co-BsLuxS-HT mutant was performed.  
                                      
The fluorescence proximity assay requires a thiol reactive fluorophore (see Fig. 4.4) attached 
to a properly-folded Co-BsLuxS-HT variant. For the attachment of a thiol-reactive 
fluorophore without any obstruction, a single surface accessible cysteine (–SH) is required on 
the Co-BsLuxS-HT enzyme. In order to keep the enzyme variant in its native folded form, the 
position of the cysteine for the attachment of the fluorophore should not be at either the active 
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site or the dimer interface. A catalytically misfolded Co-BsLuxS-HT enzyme could deter 
dimerization on its own and in that case it would be difficult to determine if the inhibitor was 
responsible for dimerization inhibition. 
 
Fig. 4.4 | Examples of Thiol-Reactive Fluorophores. (a) 5-iodoacetamidofluorescein (b) Dansyl aziridine (c) 
DDC (d) Badan (e) Acrylodan (f) IAEDANS (g) Dapoxyl (h) PyMPO (i) IAANS. 
 
The two steps to synthesize a fluorophore-attached, properly-folded single-cysteine Co-
BsLuxS-HT mutant: (1) prepare a catalytically active Co-BsLuxS-HT variant with a single 
surface accessible cysteine and (2) attach a fluorophore to the active Co-BsLuxS-HT mutant.  
Efforts towards achieving an active Co-BsLuxS-HT variant for eventual fluorophore 
attachment (step 1) are explained in the following sections.    
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The wild type Co-BsLuxS-HT enzyme protein has four native cysteines at positions 22, 41, 
84 and 126. The C84 position was not an appropriate option for fluorophore attachment 
because it is known to reside in the enzyme active site at the dimer interface.10 Therefore, 
possibilities for a fluorophore-attachment site on Co-BsLuxS-HT include either: (a) one of 
the three native cysteines at positions 22, 41 and 126 (see Fig. 4.5) or (b) an amino acid 
elsewhere which could be mutated to cysteine keeping the catalytic properties of the enzyme 
intact. The following sections describe in detail the efforts made towards preparing a Co-
BsLuxS-HT variant having a single surface-accessible cysteine residue that retains wild type 
catalytic activity.  
 
 Fig. 4.5 | Structure of BsLuxS Monomer showing the Position of the Three Native Cysteines. The cysteines 
positioned at 22, 41, 84 and 126 (encircled in red) in a LuxS monomer of Bacillus subtillis. Alpha chains, beta 
sheets, loops are shown in orange, yellow and white color respectively. This figure was generated using the 
DeepView software program. 
 
4.1 | Preparing an Active Co-BsLuxS-HT Variant with a Single Surface Accessible 
Cysteine from Three Native Cysteines (22, 41, and 126).  The four native cysteines present 
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in a wild type Co-BsLuxS-HT are at positions 22, 41, 84 and 126. The best possible option of 
using a native cysteine for fluorophore attachment was hypothesized to be cysteine 41 
because of its presence on the outer loop of the protein and it is not involved in either active 
site or dimer interface. The other three positions of native cysteine were not expected to be 
suitable for fluorophore attachment. The cysteine at 84 position, resides in the enzyme’s 
active site (see Section 4.4), therefore a mutation here turns the enzyme inactive which has 
been demonstrated by Pei et al.9 Cysteine 22 is present on a β-strand at the dimer interface 
and derivatization at this position could therefore hamper enzyme dimerization. The cysteine 
126 is positioned in the ligation sphere of the metal ion of Co-BsLuxS-HT, making this a 
largely inaccessible cysteine for fluorophore attachment. The derivatization at 126 position 
might dislocate the cobalt ion leading to the loss of metal ion from the enzyme, turning the 
enzyme catalytically inactive (and yellow instead of its native blue color). Mutations at all 
three of these native cysteine positions were attempted in order to analyze all the available 
possibilities in the wild type Co-BsLuxS-HT enzyme. If the enzyme was found catalytically 
active even after the mutations at any of these three abovementioned native positions, it 
would be used for fluorophore attachment for detection of dimerization inhibitors. 
 
4.1.1 | Generation of Co-BsLuxS-HT Mutants by Site-Directed Mutagenesis. Different 
combinations of mutants using the native cysteines were generated, to acquire a catalytically 
active enzyme mutant with a single surface accessible cysteine available for fluorophore 
attachment. Table 4.1 shows the Co-BsLuxS-HT mutants, some of them were expected to be 
catalytically active with a surface accessible cysteine. The Co-BsLuxS-HT mutants with a 
C84A mutation were expected to turn the enzyme catalytically inactive, but they were still 
generated to be used as a negative control.  
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Table 4.1 | Co-BsLuxS-HT mutants. The four types of mutations to be performed and the different Co-BsLuxS-HT mutants required. The mutants with C84A 
mutation were prepared to be used as negative controls. The presence of C126A and C22A at the active site and dimer interface made it little unsure that mutation at 
these sites would still render the enzyme active. 
Native Cysteine Positions Co-BsLuxS-HT Mutants 
22 41 84 126 
Expected to be Catalytically 
Active 
Single Co-BsLuxS-HT Mutants 
S1 A C C C May be 
S2 C A C C Yes 
S3 C C A C No 
S4 C C C A May be 
Double Co-BsLuxS-HT Mutants 
D1 A A C C May be  
D2 C A A C No 
D3 C C A A No 
D4 A C C A May be 
D5 A C A C No 
D6 C A C A May be 
Triple Co-BsLuxS-HT Mutants 
T1 A A A C No 
T2 C A A A No 
T3 A C A A No 
T4 A A C A May be 
Quadruple Co-BsLuxS-HT Mutant 
Q A A A A No 
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4.1.1.1 | General Parameters for Generation of Mutants by Site-Directed Mutagenesis. 
The general parameters for the generation of mutants were the same as mentioned previously 
(see Section 3.2.1).  
 
4.1.1.2 | Generation of Co-BsLuxS-HT Mutants by Site-Directed Mutagenesis. The 
generation of a single mutant Co-BsLuxS-HT C84A (S3) and its use as a negative control in 
the activity assay of Co-BsLuxS-HT has been discussed previously in Chapter 3 (see Section 
3.2).  
 
Appropriate primer pairs encoding for the mutations C22A, C41A and C126A were designed 
using PrimerX. The primer design guidelines of QuikChange® site directed mutagenesis kit, 
such as GC% (the strength of the fragment based on the number of triple bonded G and C 
nucleotides present should be minimum 40%), Tm (melting temperature ≥75°C) and length 
(25-45 bp), were used for the design of these primers to ensure their integrity at varying PCR 
conditions (see Table 4.2). The purified plasmid encoding for the wild type Co-BsLuxS-HT 
was used as a template. The SDM, Pellet Paint® Co-Precipitant and transformation 
procedures and conditions were the same as previously mentioned (see Section 3.2.2). 
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Table 4.2 | Primers Encoding Single Mutations. The primers designed using PrimerX for the synthesis of single 
mutants along with their characteristics is shown. 
 
Once the colonies of transformed cells were selected and grown, the purified plasmids 
containing the desired mutations were sent for sequencing (Sequetech).b The sequences were 
aligned using the SeqMan Pro module of DNAStar Lasergene 8.0 to determine if the single 
Co-BsLuxS-HT mutations were achieved. All the desired single Co-BsLuxS-HT mutations 
S1, S2 and S4 (see Table 4.1) were successfully made. 
 
Initially, Co-BsLuxS-HT C84A (S3) was used as template for the generation of the double 
Co-BsLuxS-HT C41AC84A (D2) mutant because it was the first mutant to be generated and 
purified. The C41A primers used for the mutation are shown in Table 4.2. The method for 
synthesis of the double Co-BsLuxS-HT C41AC84A (D2) mutant was also the same as 
provided in Section 3.2.2. The colonies acquired after transformation of the plasmids 
(expected to encode for mutation D2) into competent bacterial cells were grown in LB Amp75 
media for selective growth of bacterial cells carrying the plasmid with ampicillin resistance 
                                                 
b Due to easy delivery of samples and prompt sequencing results received from Sequetech, the sequences were 
sent for sequencing to Sequetech instead of Seqwright where the sequences have been sent previously (see Section 
2.2). 
Primers 
Encoding 
Mutation 
Primers Length 
(bp) 
GC 
% 
Melting 
Temp. 
(°C) 
C22A 5'GTTGCTCCATATGTAAGACATGCG
GGCGTGCATAAAGTGGGAAC 3' 
 
44 50.0 79.7 
C41A 5’GTTGTAAATAAATTTGACATTCGT
TTTGCGCAGCCAAATAAACAGGCG
ATGAAGCC 3' 
 
56 39.3 80.4 
C126A 5'GCTGCGAATGAAAAGCAGGCGGG
CCAAGCGAAGCTTCATG 3’ 
 
40 57.5 80.0 
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(see Section 3.1). The plasmids purified from the bacterial cells present in the culture, using 
Fermentas GeneJET™ plasmid purification miniprep kit, were sent for sequencing. The 
sequences were found to contain only the single C41A (S2) mutation (see Table 4.3) instead 
of the expected and desired Co-BsLuxS-HT C41AC84A (D2) mutation. This suggested that 
in the presence of C84A mutation makes it difficult to incorporate another mutation because 
the C84A mutation reverted itself back to the C84C, delivering a sequence only with a single 
mutation. The reason for this reversion is unknown. When this method failed to produce the 
desired results, two new techniques were used to achieve double mutants again using Co-
BsLuxS-HT C84A (S3) as template and to confirm our hypothesis of C84A reversion. 
 
The new techniques employed for acquiring double mutants using Co-BsLuxS-C84A (S3) as 
template were (a) cloning and (b) use of non-overlapping primers instead of overlapping 
primers. However, both the techniques also resulted in a reversion of the C84A to C84C 
when the second mutation was attempted to be incorporated (see Table 4.3). Efforts toward 
acquiring the double Co-BsLuxS-HT C22AC84A (D5) mutant using Co-BsLuxS-HT C84A 
(S3) mutant as template by cloning technique is described in detail in the following sections. 
 
 
 
 
 
 
 
 
  76
Table 4.3 | Reversion of C84A mutation. The Co-BsLuxS-HT C84A (S3) mutant when used as the template for 
the generation of the double Co-BsLuxS-HT mutants were found to revert to C84C. The attempts for achieving the 
double Co-BsLuxS-HT mutants using C84A (S3) as a template and new techiniques (cloning and use of non-
overlapping primers) are explained in Sections 4.1.1.2.1 and 4.1.1.2.2, repectively.                           
Mutation desired Template 
Used 
Primer Used Technique  
used 
Mutant 
achieved 
C41AC84A (D2) C84A (S3) C41A  
Overlapping  
SDM C41A (S2) 
C22AC84A (D5) C84A (S3) C22A  
Overlapping 
SDM C22A (S1) 
C22AC84A (D5) C84A (S3) C22A  
Overlapping 
Cloning C22A (S1) 
C22AC84A (D5) C84A (S3) C22A  
Non-overlapping 
SDM C22A (S1) 
C126AC84A (D3) C84A (S3) C126A  
Non-overlapping 
SDM C126A (S4) 
C41AC84A  (D2) C84A (S3) C41A  
Non-overlapping 
SDM  No mutation 
found 
 
4.1.1.2.1 | Cloning Technique for Achieving a Double Co-BsLuxS-HT Mutant. The term 
‘cloning’ here refers to molecular cloning which involves processes used to create copies 
of small molecules, e.g. DNA fragments. Due to failed attempts of achieving double mutants 
by site directed mutagenesis using S3 mutant as template, cloning of the mutated DNA 
fragments encoding the double mutation and incorporation into the plasmid vector pET-
22b(+) was expected to deliver results. Initially, cloning technique was used to acquire a 
double Co-BsLuxS-HT C84AC22A (D5) mutant. This was done in order to determine if the 
cloning technique worked. If this technique was successful in obtaining the D5 mutant, it was 
planned to be eventually used for acquirement of other double, triple and quadruple variants. 
 
For the incorporation of the cloned DNA fragment containing the desired mutation, a pET-
22b(+) plasmid vector was required (see Section 3.1). This was acquired using wild type 
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purified Co-BsLuxS-HT plasmid. The wild type purified Co-BsLuxS-HT plasmid was 
digested with the restriction enzymes Nde-I and Xho-I. As mentioned previously (Section 
3.1), these restriction enzymes had been used to incorporate the DNA fragment coding for the 
Bacillus subtillis LuxS by Pei & coworkers.9 Therefore, these enzymes were used to remove 
that DNA fragment from the vector.9 Along with the Nde-I and Xho-I digested wild type Co-
BsLuxS-HT plasmid, five other samples were prepared: (a) supercoiled/undigested plasmid 
(wild type Co-BsLuxS-HT), (b) Nde-I digested plasmid (linear Co-BsLuxS-HT plasmid 
because of a single cut near DNA insert), (c) Xho-I digested plasmid (linear Co-BsLuxS-HT 
plasmid because of a single cut near DNA insert), (d) Pst-I digested plasmid (linear Co-
BsLuxS-HT plasmid because of a single cut away from the DNA insert), (e) blank containing 
no plasmid. The digested products along with the blank were loaded on a 1% agarose gel as 
good resolution of DNA fragments of size 0.5-10 kb is usually achieved using 1% agarose 
gels. The other samples were electrophoresed along with doubly-digested plasmid to compare 
the bands and to determine if the plasmid was doubly-digested by both Nde-I and Xho-I. The 
expected band for sample (a) was a thick band near 5-6 kb bands of ladder as the Co-BsLuxS-
HT protein is 5.5 kb and circular. The samples (b), (c), and (d) when digested by the enzymes 
were expected to turn the circular DNA to linear form. The linear form of DNA travels faster 
in comparison to circular form of DNA hence the bands for these samples were expected to 
lie near and little farther from the band of sample (a). The band for the double digested 
plasmid was expected near ~5.4 kb due to removal of the DNA insert of ~500 bp. A small 
band of ~500 bp for the removed DNA insert from the plasmid vector pET-22b(+) was also 
expected. For the blank sample no band was expected as it did not contain DNA.  
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The bands on the gel were visualized with UV light because the ethidium bromide dye 
present in the gel fluoresces under UV light when intercalated into DNA. Two bands were 
acquired for supercoiled Co-BsLuxS-HT (sample a), as obtained previously by SDS-PAGE 
gels (see Fig. 4.6 & 3.9). Thin bands for the singly digested plasmids (samples b, c and d) 
were also obtained near 5 kb band of ladder, as expected (see Fig. 4.6). No band for blank 
was obtained. A broad band near 5 kb band of ladder was acquired for the pET-22b(+) vector 
(doubly digested sample), as expected (see Fig. 4.6). A small band near ~500 bp band of 
ladder for the removed DNA insert from the plasmid vector was not obtained. The possible 
reason could be the use of 1% agarose gel for resolution as resolution of tiny DNA fragments 
a gel of higher percentage of agarose is typically used. Assuming that the double-digest 
worked despite the absence of the 500 bp band, the band for the vector was cut from the gel 
using a sterilized blade. The gel fragment containing the desired plasmid was purified using 
NucleoSpin® gel extraction kit and stored at -80°C in an Eppendorf tube. This kit helps in 
extracting the DNA from the gel fragment by solubilizing the gel and removing it from the 
solution containing DNA. The purified pET-22b(+) plasmid vector was saved at -80°C until 
the clones of DNA fragment encoding for double mutation were acquired. 
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Fig. 4.6 | Agarose Gel Electrophoresis of pET-22b(+) Vector Digests. The picture shows the bands for different 
samples such as undigested Co-BsLuxS-HT/supercoiled, blank, Nde-I digested plasmid sample, Xho-I digested 
plasmid sample, Pst-I digested plasmid sample and plasmid vector pET-22b(+) obtained after digestion by two the 
restriction enzymes Nde-I and Xho-I.  
 
The DNA fragment coding for the desired LuxS mutation was generated after acquiring a 
purified plasmid vector pET-22b(+). Two kinds of primers were required: a full length primer 
coding for the template Co-BsLuxS-HT C84A, and a C22A primer. These were designed 
manually using the DNA sequence of Bacillus subtillis coding for LuxS. The primers and 
their characteristics are listed in the Table 4.4. The designed primers for cloning technique 
were sent to IDT for synthesis.  
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Table 4.4 | Cloning Primers. The primers manually designed for cloning technique to incorporate the C22A 
mutation into Co-BsLuxS-HT C84A template. 
 
Two PCR reactions were performed. One reaction was run with full length reverse primer and 
C22A forward primer in order to obtain DNA fragments with C22A mutation on the 5’→3’ 
strand (see Fig. 4.7). The second PCR reaction was run using full length forward primer and 
C22A reverse primer to obtain DNA with C22A mutation on the 3’→5’ strand. Reaction 
buffer, distilled water, dNTP’s and the Ex Taq™ DNA polymerase enzyme were added to 
both reaction mixtures. The SDM kit used for this mutagenesis was TaKaRa Ex Taq™ RT-
PCR kit. Both reactions were performed in parallel. After this PCR round, a second round of 
PCR was performed using 1 µL of the PCR product each from the abovementioned PCR 
reactions as template and full length forward and reverse primers to obtain DNA fragments 
with C22A mutation on both the strands of DNA. Running different rounds of PCR reactions 
increased the efficiency and chance of obtaining the DNA fragments encoding C84AC22A 
mutation. 50 µL of the PCR product acquired from the second round of PCR was purified 
using NucleoSpin® PCR clean-up kit. This step ensured removal of any other impurities (e.g. 
dNTP’s or unused primers and template from the PCR product), which would eventually 
increase the efficiency by increasing amount of DNA incorporation in to the plasmid vector. 
A volume of 15 µL of the clean PCR product was then digested by the restriction enzymes 
Primers 
encoding for 
mutation 
Primers Length 
(bp) 
GC % Melting 
Temp. (°C) 
Full Length 
Primers 
5'GGAAGGCCATATGCCTTCAG
TAGAAAGTTTTGAG 3’ 
 
34 44.1 66.6 
 
C22A 
 
5’GTAAGACATGCCGGCGTGCA
TAAAG 3' 
 
25 52 62.4 
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Nde-I and Xho-I. This was done to create sticky ends in the DNA fragment, which would 
assist in proper incorporation into the plasmid vector (see Fig. 4.7). 
 
The pET-22b(+) vector was ligated with the DNA fragment coding for the desired mutation 
using the ligation enzyme T4 DNA polymerase at 4°C overnight along with a blank sample 
containing distilled water instead of DNA in the reaction mixture (see Fig. 4.7). The next day, 
the ligated mixture was incubated at room temperature for 45 min. to denature the T4 DNA 
polymerase enzyme. To remove any remaining enzyme from the ligation mixture, heat 
inactivation was done at 70°C for 10 min. Immediately after heat inactivation, the reaction 
mixture was kept on ice and 2 µL of the transformation mixture was transformed into no heat 
shock Z-Competent™ cells. This transformation mixture was spread on LB Amp200 plates for 
selective growth of the bacterial cells (see Section 3.1) and incubated overnight at 37°C. No 
colonies were achieved. After three rounds of cloning using different competent cells (such as 
JM109 competent cells, BL21(DE3) competent cells and XL-10 ultracompetent cells), 27 
colonies were acquired in last round using BL21(DE3) competent cells. Out of 27 colonies, 3 
colonies were picked and their plasmids were purified by the GeneJET™ plasmid purification 
kit to be sent for sequencing. The sequences were aligned with the wild type Co-BsLuxS-HT 
sequence to determine if they had any mutations. One of the plasmid samples out of three, 
encoded for the C22A (S1) mutation. Eventually, after all the efforts, the described cloning 
approach failed to deliver a double mutated Co-BsLuxS-HT C84AC22A (D5) mutant. 
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Fig. 4.7 | Cloning Technique. (a) A purified pET-22b(+) vector was acquired by removing the LuxS DNA insert from wild type Co-BsLuxS-HT plasmid (with 
DNA insert coding for BsLuxS in blue). (b) Two reactions were run in first round of PCR with Co-BsLuxS-HT C84A (green) as template and primers used were 
C22A (red) and full length (FL in green). (C) The PCR products from PCR round 1 were mixed in 1:1 ratio and used as templates with full length (FL) primers to 
get full length DNA fragments encoding for double C22AC84A mutation. The PCR product was then digested by NdeI and XhoI to create sticky ends in the DNA 
fragment. (d) The purified vector and the DNA fragment with C84AC22A mutation was ligated in presence of T4 DNA Polymerase at 4°C. (e) The plasmid 
resulting from the ligation encoding for the double mutation C22AC84A was transformed into competent cells.  
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While the efforts towards obtaining a double mutated Co-BsLuxS-HT by cloning technique 
were ongoing, the design and synthesis of non-overlapping primers was also in progress. The 
following sections provide detailed analysis of the idea and usage of non-overlapping primers 
for achieving Co-BsLuxS-HT double mutant.39  
 
4.1.1.2.2 | Using Non-Overlapping Primers for Acquiring a Double Co-BsLuxS-HT 
Mutant. The idea of achieving the Co-BsLuxS-HT double mutant using the non-overlapping 
primers was acquired from a methodology article.39 This article mentions using non-
overlapping primers for increasing the efficiency of site directed mutagenesis using 
QuikChange® SDM kit. The problem associated with using overlapping primers is the 
possibility of self-annealing and the inability to use newly synthesized DNA strands as 
templates for the next rounds due to presence of nick/break (see Fig. 4.8). The presence of 
nick in newly formed DNA strands hampers the rapid synthesis of new DNA fragment and 
this leads to decreased efficiency of the site directed mutagenesis. Addition of more DNA 
template to combat this problem, increases the chances of synthesis of hemi-methylated DNA 
(newly synthesized strands complexed with a parental strand), which are not able to be 
digested by Dpn-I, resulting in recovery of non-mutated DNA.  
 
Non-overlapping primers are short DNA sequences with overlapping sequences at their 5’ 
end and non-overlapping sequences at their 3’ end. The melting temperature of these primers 
is 5 to 10°C higher than the melting temperature of overlapping primers.39 These primers 
don’t have a length restriction, and mutation sites could be present in both the overlapping 
and non-overlapping regions of the primer. The use of non-overlapping primers increases the 
mutation efficiency by decreasing primer self-annealing and also by using of newly-formed 
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DNA as templates in PCR amplification cycles.39 The nick in the newly synthesized DNA is 
bridged by the non-overlapping sequences, thereby rendering newly formed full length DNA 
fragments capable of acting as templates. The promising experimental results, reduction in 
cost and ease of using an additional one step in mutagenesis protocol, compelled us to use 
this technique for acquiring a double Co-BsLuxS-HT mutant. 
 
Fig 4.8 | Overlapping Primers vs. Non-overlapping Primers. (A) Using overlapping primers (depicted by black 
arrows) designed as mentioned in QuikChange™ protocol, fail to generate a new DNA from a newly synthesized 
DNA strand due to presence of a nick. (B) Using non-overlapping primers (depicted by black non-overlapping 
arrows) for the generation of DNA from a newly synthesized strand works well due to the absence of a nick.39 
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The non-overlapping primers for Co-BsLuxS-HT were designed using the PrimerSelect 
module of Lasergene 8.0. The DNA sequence of Co-BsLuxS-HT was used as the template for 
designing of these non-overlapping primers. All forward and reverse sequences were 
designed individually and therefore they all had different melting temperatures, GC contents 
and lengths (see Table 4.5). The designed non-overlapping primers were sent to IDT for 
synthesis and used later for the generation of double mutated Co-BsLuxS-HT by site directed 
mutagenesis. 
 
Table 4.5 | Non-Overlapping Primers. The non-overlapping primers designed with non overlapping 3’ end 
sequences and their parameters. 
Primers 
encoding for 
mutation 
Primers Tm 
no 
GC 
% 
Length 
(bp) 
C84AF 5’CAATGGGCGCGCAGACAGGCTAT 
TATCTAGTTGTGAGCGGAGAG 3’ 
 
79.3 53.5 43 
C84AR 5’CTGTCTGCGCGCCCATTGGAGAA 
ATATCAATGATATCAAAATG 3’ 
 
76.7 40.9 43 
C126AF 5’AAAAGCAGGCGGGCCAAGCGAA 
GCTTCATGATCTGGAAGGCG 3’ 
 
83.4 52.4 42 
C126AR 5’GCTTGGCCCGCCTGCTTTTCATTCGC
AGCAGGTATTTCTGTA 3’ 
 
80 52.4 42 
C22AF 5’TAAGACATGCGGGCGTGCATAA 
AGTGGGAACAGAC 3’ 
 
73.4 51.4 35 
C22AR 5’TGCACGCCCGCATGTCTTACAT 
ATGGAGCAACAAC 3’ 
 
75.1 51.4 35 
C41AF 5’CATTCGTTTTGCGCAGCCAAATAA 
ACAGGCGATGAAGCCTGACACCA 3’ 
 
83 48.9 47 
C41AR 5’GTTTATTTGGCTGCGCAAAACGAATG
TCAAATTTATTTACAACGCCG3’ 
 
77.1 38.3 47 
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At first, the single Co-BsLxS-HT C84A (S3) mutant was used as template for the generation 
of double mutated Co-BsLuxS-HT (D2, D3 and D5) using non-overlapping primers. But, as 
mentioned previously, the C84A mutation reverted back to C84C (see Table 4.3). These 
results confirmed that C84A mutation reverts back on incorporation of other mutations. 
Henceforth, for the generation of the next batch of mutants, the C84A mutation was 
incorporated last in those variants with a C84A requirement.  
 
For the generation of double Co-BsLuxS-HT mutants D1, D2, D3, D4, D5 and D6, the single 
mutants S1, S2 and S3 were used as templates. To make a comparison between the mutation 
results from the use of two kinds of primers, both overlapping and non-overlapping primers 
were used in the SDM protocol. The method of site directed mutagenesis was the same as 
discussed earlier in Section 3.2.2. 
 
Most of the Co-BsLuxS-HT double mutants were acquired using the non-overlapping primers 
except C22AC41A (D1), C22AC126A (D5) and C22AC84A (D4) (see Table 4.6), although 
they were achieved using overlapping primers. The presence of a common C22A mutation in 
all the above mentioned three sequences suggests some correlation. It is hard to deduce some 
possible reasons at this time, but this fact might be considered useful while generating a 
mutant with a C22A mutation for later site directed mutagenesis experiments. However, the 
double Co-BsLuxS-HT mutants were finally achieved after extensive troubleshooting. 
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Table 4.6 | Results of Double Mutation. The Co-BsLuxS-HT double mutants achieved using non-overlapping 
primers and overlapping primers. 
Double 
Mutants 
Required 
Primers Used Total no. of 
sequences sent 
for sequencing 
Sequences 
containing 
mutation  
Co-BsLuxS-HT 
Double Mutant 
Achieved 
D1 Non-overlapping  2 0 no 
D1 Overlapping 2 1 yes 
D2 Non-overlapping 2 2 yes 
D3 Non-overlapping 2 1 yes 
D4 Overlapping  2 1 yes 
D5 Non-overlapping  2 0 no 
D5 Overlapping 2 2 yes 
D6 Non-overlapping 2 2 yes 
D6 Overlapping 2 2 yes 
 *No colonies were achieved in an attempt to get LuxSC126AC84A and LuxSC41AC84A mutations using overlapping primers. 
No colonies were achieved for C22AC84A using non-overlapping primers. Therefore they are not mentioned in the table above. 
                
For the synthesis of triple-mutant Co-BsLuxS-HT variants, again both overlapping and non-
overlapping primers were used (see Table 4.2 and 4.5). The doubly-mutated templates used 
for acquiring these double mutants were D1, D5 and D6. These double mutants did not 
contain the C84A mutation to ensure no C84C reversion as previously discussed (see Table 
4.3). The method for the synthesis of these triple mutants using site directed mutagenesis was 
the same as discussed in the Section 3.2.2. The non-overlapping primers again proved to be 
an important part of site directed mutagenesis protocol in acquiring the desired mutations (see 
Table 4.7) by delivering three triple mutants (T1, T2 and T3). 
 
Even after performing several rounds of site directed mutagenesis and using both kinds of 
primers, it became difficult to acquire one of the four triple mutants C22AC126AC41A (T4). 
The reason for the continuous failures is still unknown. 
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Table 4.7 | Triple Co-BsLuxS-HT Results. The use of non-overlapping primers delivered three triple mutation 
out of four. 
Triple 
Mutants 
Required 
Primers Used Total no. of 
sequences sent for 
sequencing 
Sequences 
containing 
mutation  
Co-BsLuxS-HT 
Triple Mutant 
Achieved 
T1 Non-overlapping 2 2 yes 
T1 Overlapping 2 0 no 
T2 Non-overlapping 2 1 yes 
T2 Overlapping 2 0 no 
T3 Non-overlapping 2 1 yes 
T3 Overlapping 2 0 no 
T4 Non-overlapping N/A N/A N/A 
T4 Overlapping N/A N/A N/A 
*For Triple Co-BsLuxS-HT C22AC41AC126A no colonies were achieved using either of the kinds of the primers. 
 
A quadruple mutant was also designed containing all native cysteines mutated to be used as 
negative control. The non-overlapping primers and overlapping primers (C22A, C41A and 
C126A) were used to generate the quadruple mutant, and the three triple mutants acquired 
(T1, T2 and T3) were used as templates. The method used for site directed mutagenesis was 
the same as mentioned previously in Section 3.2.2. No colonies were achieved using all the 
kinds of primers and triple mutants as templates. Hence, no further efforts were made towards 
achieving this mutant. 
 
4.1.2 | Overexpression and Purification of Mutant Proteins. After acquiring almost all the 
desired Co-BsLuxS-HT mutations (except T4 and Q mutations) the bacterial cells carrying 
plasmids encoding for the mutations were overexpressed and purified. The details and 
discussion for overexpression and purification of these mutants is provided in the following 
sections. 
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4.1.2.1 | General Parameters for Protein Purification. The general parameters for the 
overexpression and purification of the mutant proteins is the same as described previously 
(see Section 3.1.2 & 3.1.3). 
 
4.1.2.2 | Purification of the Co-BsLuxS-HT Mutants. While single Co-BsLuxS-HT 
mutants were overexpressed and purified by the method discussed earlier (see Section 3.1.2 
and 3.1.3), an interesting observation was made. The pellets for single Co-BsLuxS-HT 
mutants obtained after overexpression were different in color. Some of the pellets were 
yellow whereas some of them were grayish blue. The pellets for enzyme variants with the 
C126A mutation (D3, D4 and D6) were yellow, as well as the protein purified using some of 
these pellets was also yellow (see Table 4.8). The probable reason for this was the presence 
of cysteine 126 in the ligation sphere of the metal, where a mutation was likely to make the 
metal unstable. Presumably the metal is not able to bind as it does in a wild type Co-BsLuxS-
HT, and this result in the discoloration of the protein. Whereas the protein purified from a 
grayish blue colored pellet was always blue, possibly due to the presence of cobalt bound 
enzyme (see Section 3.1). These observations helped to determine the presence of a blue 
natively-folded enzyme protein before continuing with the purification procedure.  
 
Table 4.8 | Color of the Pellet Indicating Presence of the Metal Bound Enzyme. The experimental results 
demonstrating that the blue colored pellet delivers a cobalt metal bound Co-BsLuxS-HT enzyme. 
Co-BsLuxS-HT Mutant   Color of pellet Color of the Purified Protein 
S1 Grayish blue Dark blue 
S2 Yellow Yellow 
S4 Yellow Yellow 
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Because this observation was made while purifying the pellets for single Co-BsLuxS-HT 
mutants, typically only pellets with a grayish blue color were purified. The BL21(DE3) 
competent cells carrying the plasmid coding for the double mutations D1, D2, D3, D4, D5 
and D6 were overexpressed and 2L pellets were obtained (see Section 3.1.2).  
 
Considering the C84A mutation renders the enzyme inactive, only the three double Co-
BsLuxS-HT mutants (D1, D4 and D6) without C84A mutation were purified (see Table 4.9). 
Although the pellets for the double mutations D4 and D6 were yellow, suggesting misfolded 
protein, they were still purified to analyze activity because the color of the pellet did not 
indicate any information about enzyme’s activity. The method for purification of these double 
mutants was similar to the method discussed previously (see Section 3.1.3). 
 
Table 4.9 | Purification of Double Co-BsLuxS-HT Mutants. The mutants were lysed and purified based on the 
pellet color indicating the presence of properly-folded protein. D2 was not purified, although the color of the pellet 
acquired was grayish blue, because it had C84A mutation which was known to turn the enzyme inactive.9 
Co-BsLuxS-HT 
Double Mutants 
Color of the Pellet Protein Purification 
Performed 
D1 Grayish  blue Yes 
D2 Grayish blue No 
D3 Yellow No 
D4 Yellow Yes 
D5 Yellow No 
D6 Yellow Yes 
 
The bacterial cells containing the plasmid coding for the triple mutants were grown and 
overexpressed by the same method as mentioned in Section 3.1.2. A blue pellet obtained for 
C22AC41AC84A (T1) suggested proper folding of the metal bound protein (see Table 4.10). 
The other two mutants (T2 and T3) were yellow in color, probably due to misfolding of the 
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native protein and loss of cobalt metal from the enzyme as discussed in the previous sections. 
Two triple mutants (T1 & T2) of the three mutants were lysed and purified. Although these 
mutants had C84A mutation, they were purified and assayed to be used as negative control 
and to determine if the mutation allows proper protein folding.  
 
Table 4.10 | Purification of Triple Co-BsLuxS-HT Mutants. The triple Co-BsLuxS-HT mutants were lysed and 
purified based on their pellet color indicating the presence of properly folded protein. 
Co-BsLuxS-HT  
Triple Mutants 
Color of the Pellet  Protein Purification 
Performed 
T1 Grayish blue Yes 
T2 Yellow Yes 
T3 Yellow No 
 
The method for purification of Co-BsLuxS-HT triple mutants was the same as discussed in 
section 3.1.3. 
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Table 4.11 | Summary Table. The primers used to get Co-BsLuxS-HT mutants, the color of the 2 L pellets of the mutants, the determined protein concentration of 
the mutants and the results of the activity assay of the purified mutants is shown in the table. None of the mutants generated using native cysteines present on Co-
BsLuxS-HT were found to be active as explained in Section 4.1.4. The mutant D2 was not purified, although the color of the pellet acquired was grayish blue, 
because it had C84A mutation which was known to turn the enzyme inactive.9  
  
 
 
Co-BsLuxS-HT 
mutant 
Primer used to 
achieve mutant 
Pellet color Protein purified Protein conc. mM Catalytic activity 
detected 
S1 Overlapping Grayish blue Yes 0.877 No 
S2 Overlapping Yellow Yes 0.121 No 
S3 Overlapping Grayish blue Yes 0.923 No 
S4 Overlapping Yellow Yes 2.16 No 
D1 Overlapping Grayish blue Yes 2.96 No 
D2 Non-overlapping Grayish blue No N/A N/D 
D3 Non-overlapping Yellow No N/A N/D 
D4 Overlapping Yellow Yes 1.79 No 
D5 Overlapping Yellow No N/A N/D 
D6 Overlapping N/A N/A N/A N/D 
D6 Non-overlapping Yellow Yes 0.4 No 
T1 Non-overlapping Grayish blue Yes 0.423 No 
T2 Non-overlapping Yellow Yes 0.434 No 
T3 Non-overlapping Yellow No N/A N/D 
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4.1.3 | Estimation of Protein Concentration by Bradford Dye Assay. The amount of the 
mutant enzyme proteins in the purified protein mixture was measured by the optimized 
Bradford dye assay using transparent-bottom 96-well plates (Section 3.1.5). The linear 
equation of the standard curve was used to determine the amount of protein in the purified 
mixture (see Appendix A) and the units were converted from µg to mM to determine 
concentration. 
 
4.1.4 | Ellman’s Assay for Activity Detection of Co-BsLuxS-HT Mutants. The Ellman’s 
assay was performed to determine the catalytic activity of the mutants, as described 
previously (see Section 3.4). None of the Co-BsLuxS-HT mutants generated from the native 
cysteines was found to be active by the activity assay. The Michaelis-Menten curve for each 
of the mutants tested is provided in the Appendix B. 
 
Because none of the Co-BsLuxS-HT mutants generated from the native cysteines were active, 
the focus shifted to find some peripheral amino acids which could be mutated to cysteine, 
keeping the enzyme active and properly-folded while providing surface accessibility to the 
fluorophores to be atttached. The work towards obtaining an active Co-BsLuxS-HT mutant 
using non-native cysteines is explained in the following section. 
 
4.2 | Acquiring an Active Co-BsLuxS-HT Mutant with One Surface Accessible Cysteine 
from Non-native Cysteine Residues. After the failed attempts to obtain an active Co-
BsLuxS-HT mutant using native cysteines, the other option was to mutate a non-cysteine 
amino acid present on the surface of the enzyme to cysteine. The technique involving use of 
non-native cysteines for attachment of fluorophores to an enzyme with no native surface 
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cysteines have been previously reported by Zhu and Pei.40 The DeepView program Swiss 
PDB was used to find the best possible amino acid present on the periphery of Co-BsLuxS-
HT enzyme for substitution (PDB code: 1IE0). The first requirement was that this amino acid 
should be surface accessible for the successful attachment of a fluorophore. Ideally, this 
amino acid should be non-polar so that its mutation to cysteine is conservative but it was very 
likely that an amino acid present on the surface of enzyme will be polar. However, 
considering that the presence of one non-polar amino acid on the surface of enzyme may not 
make much difference in enzyme’s overall environment, native polar amino acids were 
considered for substitution in addition to non polar ones. Finally, such an amino acid would 
have a side chain with no intermolecular interactions with other side chains to decrease the 
risk of misfolding of the enzyme after mutation. Ultimately, three amino acids identified 
according to these requirements for substitution were: threonine at position 29, tyrosine at 
position 71, and threonine at position 116 of the Co-BsLuxS-HT enzyme (see Fig. 4.9). 
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                             (A)                                                   (B) 
 
 (C) 
 
Fig. 4.9 | Possible Sites on Surface of Co-BsLuxS-HT for Mutation to Cysteine. (A) Threonine at 29 position 
(B) Tyrosine at 71 position (C) Threonine at 116 position. All the three amino acids are present in different loops 
of the enzyme and on the periphery making them surface accessible. The loop is shown in green, carbon in white, 
oxygen in red and hydrogen in blue. This figure was generated using DeepView. 
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The surface accessibility of the threonine at position 29 determined by DeepView was 52.1%, 
DeepView also determined that the side chain of threonine 29 was not involved in any 
intermolecular bonding. This was the most surface accessible amino acid of the three 
originally identified. The neighboring amino acids are neutral glycine with the smallest side 
chain and aspartate with a bulky polar side chain.  
 
The surface accessibility of tyrosine 71 was 13% (which was the least of the three amino 
acids selected) and its side chain was also not involved in any molecular interactions as 
determined by DeepView. The presence of neighboring aspartate and lysine residues with 
bulky side chains made this position potentially unsuitable for mutation. This was due to 
possible steric bulk imposed by the neighboring residues, and this position would be used for 
fluorophore attachment.  
 
The surface accessibility of threonine 116 was 47% and also had a free side chain. Its 
neighboring amino acids were glutamate and isoleucine. The issues with using this position 
for fluorophore attachment was the same as discussed for tyrosine 71, which is the presence 
of neighboring amino acids with bulky side chains.  
 
4.2.1 | Generation of Co-BsLuxS-HT Mutants. Only non-overlapping primers were 
designed for achieving these mutations due to the promising results acquired by using them 
for attaining Co-BsLuxS-HT mutants from native cysteines (see Section 4.1.2). The non-
overlapping primers for T29C, Y71C and T116C were designed using the PrimerSelect 
module of DNAStar Lasergene 8.0 (see Table 4.12). A wild type Co-BsLuxS-HT purified 
plasmid was used as the template for the generation of these mutants. The method for site 
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directed mutagenesis using QuikChange SDM kit, Pellet Paint for concentration of PCR 
product, transformation into BL21(DE3) competent cells and plating on to LB Amp200 plates 
was the same as mentioned previously (see Section 3.3). 
 
Table 4.12 | Non-overlapping Primers Designed for Non-native Cysteine Mutants. The non-overlapping 
primers designed using PrimerSelect Module of DNA star Lasergene 8.0 to obtain T29C, Y71Cand T116C 
mutants. 
 
No colonies were achieved for the T116C mutation. Colonies acquired for the other two 
mutants (T29C and Y71C) were grown in 5 mL of LB Amp75 media. The bacterial cells 
carrying the plasmids encoding for the T29C and Y71C mutations were lysed and purified 
using GeneJET™ plasmid purification kit. The purified plasmids were sent to Sequetech for 
sequencing, and the sequences received were aligned using the SeqMan Pro module of 
Primers 
encoding 
mutation 
Primers Tm 
no 
GC 
% 
Length
(bp) 
T29CF 5’GTGCATAAAGTGGGATGCGACGGCGTTG
TAAATAAATTTGACATTCG3’ 
 
78.1 42.6 47 
T29CR 5’TTTACAACGCCGTCGCATCCCACTTTATG
CACGCCGCAATGTCTTACATATG3’ 
 
66.6 48.1 52 
Y71CF 5’GTTTACGATTCGTTCTCACGCTGAGAAA
TGCGATCATTTTGATATC3’ 
 
74.8 39.1 46 
Y71CR 5’GGAGAAATATCAATGATATCAAAATGAT
CGCATTTCTCAGCGTGAG3’ 
 
73.8 37 46 
T116CF 5’GACACAATGAAGGAAGCGGTAGAGATT
TGCGAAATACCTGCTGCG3’ 
 
78.4 48.9 45 
T116CR 5’GGCCGCACTGCTTTTCATTCGCAGCAGG
TATTTCGCAAATCTCTACCGCTTC3’ 
 
68.2 51.9 52 
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DNAStar Lasergene 8.0 to determine the presence of the mutations (see Table 4.13). Each of 
the samples sent for sequencing had the desired T29C and Y71C mutations. 
 
Table 4.13 | Sequencing Results. The samples sent for sequencing had the desired T29C and Y71C mutations. 
Co-
BsLuxS-
HT 
Mutants  
Primers Used Total no. of 
sequences sent 
for sequencing 
Sequences 
containing 
mutation  
Co-BsLuxS-HT 
Mutant 
Achieved 
T29C Non-overlapping 2 2 Yes 
Y71C Non-overlapping 2 2 Yes 
 
4.2.2 | Purification of the Co-BsLuxS-HT Mutants. The bacterial cells carrying the plasmid 
encoding for T29C and Y71C mutations were overexpressed and a 2 L pellet was acquired as 
mentioned previously (see Section 3.1). The color of the 2 L pellet for both of these 
mutations was grayish blue (see Table 4.14) and both proteins were purified after lysis from 
French press by the same method as previously described (see Section 3.1.3). 
 
Table 4.14 | Color of Pellets Acquired after Overexpression. The pellet color for both of them was grayish blue 
and hence protein purification was performed for both of them. 
Co-BsLuxS-HT  
Mutants 
Color of the Pellet  Protein Purification 
Performed 
T29C Grayish blue Yes 
Y71C Grayish blue Yes 
 
4.2.3 | Estimation of Protein Concentration by Bradford Dye Assay. The amount of 
protein present in the purified protein concentrate was measured by the Bradford dye assay as 
mentioned previously (see Section 4.1.4). The Bradford dye assay standard curves and the 
amount of protein determined for the purified proteins (shown in Table 4.15) are provided in 
the Appendix A. 
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4.2.4 | Ellman’s Assay for Activity Detection of Co-BsLuxS-HT Mutants. Once purified 
protein was acquired for the two Co-BsLuxS-HT non-native cysteine variants T29C and 
Y71C, their activities were assayed by Ellman’s assay according to the standard protocol 
provided in literature (see Section 2.4).9  
 
Table 4.15 | Summary Table. A summary of all the three mutants designed, purified and their activities assayed 
by Ellman’s assay.  
 
Co-BsLuxS-
HT mutant 
Primer used to 
achieve mutant 
Pellet color Protein 
purified 
Protein 
conc. 
mM 
Catalytic 
activity 
detected 
T29C Non-overlapping Grayish blue Yes 1.668 No 
Y71C Non-overlapping Grayish blue Yes 1.480 Yes 
T116C Non-overlapping N/A* N/A* N/A* N/A* 
* No colonies were acquired for the Co-BsLuxS-HT T116C mutant. 
 
The mutant Co-BsLuxS-HT T29C was found to be inactive in the Ellman’s assay (see 
Appendix B), whereas the other mutant Co-BsLuxS-HT Y71C was found to be active. To 
ensure that the mutant Co-BsLuxS-HT Y71C was indeed active, three replicates of activity 
assays were performed for this enzyme. The Michaelis-Menten curve including the reaction 
rate values from all three replicates of Co-BsLuxS-HT Y71C mutant is shown in Fig. 4.10. 
(The Michaelis-Menten curves for individual trials are provided in Appendix B). The kinetic 
parameters for Co-BsLuxS-HT Y71C were determined as discussed in Section 3.4.2.2.1 for 
Co-BsLuxS-HT. 
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Fig. 4.10 | Michaelis-Menten Curve for Co-BsLuxS-HT Y71C. The Michaelis-Menten curve for the active Co-
BsLuxS-HT Y71C mutant. The values of the KM and Vmax are shown on the curve. 
 
The kinetic parameters of this variant were compared to those determined for house-purified 
Co-BsLuxS-HT (see Table 4.16) to determine its activity. The KM value for the active Co-
BsLuxS-HT variant (Y71C) was 2.3 µM, which is comparable to the house-purified Co-
BsLuxS-HT enzyme value of 2.1 µM.  The KM value achieved for this variant suggested that 
the enzyme binds equally well with substrate as compared to the wild type Co-BsLuxS-HT.9 
The Vmax value determined for the Co-BsLuxS-HT was 0.1 x 10-5 µmol/s, which was 
approximately 11 fold lower as compared to house-purified Co-BsLuxS-HT (1.1 x 10-5 
µmol/s). This indicated that this variant converted one mole of substrate to product in 11 fold 
greater time as compared to house-purified Co-BsLuxS-HT.  
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Table 4.16 | Comparison of Kinetic Parameters of Enzyme. The determined kinetic parameters of Co-BsLuxS-
HT enzyme and its variant Y71C are compared with the literature values for Co-BsLuxS-HT enzyme.9 
          
Enzymes KM 
(µM) 
Vmax 
(µmol/sec.) 
kcat  
(s-1) 
kcat/KM 
(M-1 s-1) 
Co-BsLuxS-HT Y71C 2.3 ± 1.1 0.1 x 10-5 0.001  ± 0.004 0.05 x 104 
Co-BsLuxS-HT  
(house-purified) 
2.1 ± 1.4 1.1 x 10-5 0.014  ± 0.002 0.67 x 104 
Co-LuxS-HT 
(Pei and Coworkers)9  
2.3 ± 0.5 2.8 x 10-5 0.035 ± 0.003 1.6 x 104 
 
The kcat value for the variant Co-BsLuxS-HT Y71C from three replicates of activity assay 
was 0.001 s-1, which was 14 fold lower than the house-purified Co-BsLuxS-HT (0.014  ± 
0.002 s-1), indicating that this variant converts one mole of substrate into product in 14 fold 
higher time than house purified wild type Co-BsLuxS-HT. The lower value of Vmax and kcat 
affected the catalytic efficiency for Co-BsLuxS-HT Y71C (0.05 x 104 M-1s-1); it was 12 times 
lower as compared to the catalytic efficiency of house-purified Co-BsLuxS-HT (0.67 x 104 
M-1s-1).  
 
Although the KM values for this variant suggested high binding ability of this enzyme with 
substrate, the considerably lower kcat, Vmax, and catalytic efficiency values acquired for this 
variant show that it was slow to convert substrate into product as compared to wild type Co-
BsLuxS-HT (house-purified). A similar conclusion was previously derived for the house-
purified Co-BsLuxS-HT as compared to literature values (chapter 3), and therefore this Y71C 
variant is even less catalytically active as compared to the Co-BsLuxS-HT enzyme purified 
by Pei and coworkers (see Table 4.16).9  
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4.3 | Conclusion and Future Directions. Based on the surface accessibility determined using 
Deep View Swiss PDB, threonine 29 (52.1 %) was found to be more surface accessible as 
compared to tyrosine 71 (13 %). Threonine has a smaller side chain in comparison to tyrosine 
as well. Therefore, out of the two options, threonine 29 was predicted the best possible amino 
acid to mutate to cysteine and for fluorophore attachment. However, the Ellman’s activity 
assay demonstrated that Co-BsLuxS-HT T29C was found to be inactive whereas Co-BsLuxS-
HT Y71C was able to bind well with the substrate (KM = 2.3 ± 1.1 µM). Although Co-
BsLuxS-HT Y71C binds well with the substrate, it is not as catalytically active as the house-
purified wild type Co-BsLuxS-HT enzyme. It could be speculated that because the binding 
strength (KM values) of the Y71C variant and the wild type Co-BsLuxS-HT (KM = 2.1 ± 1.4 
µM) were equivalent, the Y71C variant was folding in the native wild type form. As 
mentioned earlier, some discrepancies in the purification protocol regarding oxidation of 
cysteine 84 may have led to loss of catalytic ability of the stock solution to some extent. 
Finally the presence of a new surface accessible cysteine on Y71C variant could have had 
some confounding effect upon the assay, although nothing in particular is readily obvious at 
this time. To troubleshoot, if the mutation of tyrosine 71 to cysteine is a reason for its lower 
catalytic activity, another mutant with Y71A mutation could be made. The comparison of 
activities of the two mutants i.e. Co-BsLuxS-HT Y71C and Co-BsLuxS-HT Y71A would 
help determine if the presence of the surface accessible cysteine was responsible for the 
absorbance values recorded. Additionally, if this variant is purified eliminating all the 
discrepancies resulting from oxidation of cysteine 84, possibly by using degassed buffers and 
keeping the enzyme secluded from aerobic conditions at all times (see section 3.4.2.2.1), 
there are chances to acquire a Y71C variant as active as wild type Co-BsLuxS-HT.   
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Appendix A: Bradford Dye Assay Curves 
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Fig. 1 | Bradford Dye Assay Curve for C22A. The standard curve for Bradford dye assay with the amount of 
protein determined for 1:80 diluted C22A purified protein. The protein concentration determined was 0.877 mM. 
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Fig. 2 | Bradford Dye Assay Curve for C41A. The standard curve for Bradford dye assay with the amount of 
protein determined for 1:10 diluted C41A purified protein. The protein concentration determined was 0.121 mM. 
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Bradford Dye Assay Curve for
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Fig. 3 | Bradford Dye Assay Curve for C84A. The standard curve for Bradford dye assay with the amount of 
protein determined for 1:40 diluted C84A purified protein. The protein concentration determined was 0.923 mM. 
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Fig.4 | Bradford Dye Assay Curve for C126A. The standard curve for Bradford dye assay with the amount of 
protein determined for 1:80 diluted C84A purified protein. The concentration of protein determined was 2.16 mM. 
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Bradford Dye Assay Curve for
Co-BsLuxS-HT C22AC126A
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Fig. 5 | Bradford Dye Assay Curve for C22AC126A. The standard curve for Bradford dye assay with the 
amount of protein determined for 1:80 diluted C22AC126A purified protein. The protein concentration determined 
was 1.79 mM. 
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Fig. 6 | Bradford Dye Assay Curve for C22AC41A. The standard curve for Bradford dye assay with the amount 
of protein determined for 1:80 diluted C22AC41A purified protein. The protein concentration determined was 
2.96 mM. 
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Bradford Dye Assay Curve for
Co-BsLuxS-HT C41AC126A
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Fig. 7 | Bradford Dye Assay Curve for C41AC126A. The standard curve for Bradford dye assay with the 
amount of protein determined for 1:20 diluted C41AC126A purified protein. The protein concentration determined 
was 0.4 mM. 
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Fig. 8 | Bradford Dye Assay Curve for C126AC41AC84A. The standard curve for Bradford dye assay with the 
amount of protein determined for 1:20 diluted C126AC41AC84A purified protein. The protein concentration 
determined was 0.4 mM. 
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Bradford Dye Assay Curve for
Co-BsLuxS-HT C22AC41AC84A
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Fig.9 | Bradford Dye Assay Curve for C22AC41AC84A. The standard curve for Bradford dye assay with the 
amount of protein determined for 1:20 diluted C22AC41AC84A purified protein. The protein concentration 
determined was 0.4228 mM. 
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Fig. 10 | Bradford Dye Assay Curve for T29C. The standard curve for Bradford dye assay with the amount of 
protein determined for 1:80 diluted T29C purified protein. The protein concentration determined was 1.668 mM 
  108
 
Bradford Dye Assay Curve for
Co-BsLuxS-HT Y71C
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Fig. 11 | Bradford Dye Assay Curve for Y71C. The standard curve for Bradford dye assay with the amount of 
protein determined for 1:80 diluted Y71C purified protein. The protein concentration determined was 1.480 mM. 
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Appendix B: Michaelis-Menten Analysis 
 
Michaelis-Menten curve for Co-BsLuxS-HT
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Fig. 1 | Michaelis-Menten curve for Co-BsLuxS-HT using SRH conc. 0-20 mM. The Michaelis-Menten curve 
for Co-BsLuxS-HT using a wide range (0-20 mM) of SRH concentrations is shown. The kinetic parameters 
determined were: KM = 93.5 ± 47.1 µM, Vmax = 1.5 x 10-5 µmol/s and the kcat = 0.02 ± 0.06 M-1s-1. 
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 for Co-BsLuxS-HT Round-1
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Fig. 2 | Michaelis-Menten curve for Co-BsLuxS-HT using SRH conc. 0-68 µM. The Michaelis-Menten curve 
for Co-BsLuxS-HT using 0-68 µM of SRH concentrations in round 1 is shown. The kinetic parameters determined 
were: KM = 2.3 ± 1.4 µM, Vmax = 0.7 x 10-5 µmol/s and the kcat = 0.01 ± 0.04 M-1s-1. 
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Michaelis-Menten curve
 for Co-BsLuxS-HT Round-2
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Fig. 3 | Michaelis-Menten curve for Co-BsLuxS-HT using SRH conc. 0-68 µM. The Michaelis-Menten curve 
for Co-BsLuxS-HT using 0-68 µM of SRH concentrations for round-2 is shown. The kinetic parameters 
determined were: KM value = 2.4 ± 0.4 µM, Vmax= 0.8 x 10-5 µmol/s and the kcat = 0.01 ± 0.03 M-1s-1. 
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Fig. 4 | Michaelis-Menten curve for Co-BsLuxS-HT using SRH conc. 0-68 µM. The Michaelis-Menten curve 
for Co-BsLuxS-HT using 0-68 µM of SRH concentrations for round-3 is shown. The kinetic parameters 
determined were: KM value = 1.6 ± 1.9 µM, Vmax = 0.2 x 10-5 µmol/s and the kcat = 0.02 ± 0.08 M-1s-1. 
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Michaelis-Menten curve for purified
Co-BsLuxS-HT C22A
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Fig. 5 | Michaelis-Menten curve for Co-BsLuxS-HT C22A. The Michaelis-Menten curve for the mutant Co-
BsLuxS-HT C22A is shown. Mutant was determined to have no enzymatic activity. 
 
Michaelis-Menten curve for purified
Co-BsLuxS-HT C41A
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Fig. 6 | Michaelis-Menten curve for Co-BsLuxS-HT C41A. The Michaelis-Menten curve for the mutant Co-
BsLuxS-HT C41A is shown. Mutant was determined to have no enzymatic activity. 
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Michaelis-Menten Curve for
Co-BsLuxS-HT C84A
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Fig. 7 | Michaelis-Menten curve for Co-BsLuxS-HT C84A. The Michaelis-Menten curve for the mutant Co-
BsLuxS-HT C84A is shown. Mutant was determined to have no enzymatic activity. 
 
Michaelis-Menten curve for purified
Co-BsLuxS-HT C126A
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Fig. 8 | Michaelis-Menten curve for Co-BsLuxS-HT C126A. The Michaelis-Menten curve for the mutant Co-
BsLuxS-HT C126A is shown. Mutant was determined to have no enzymatic activity. 
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Michaelis-Menten curve for
Co-BsLuxS-HT C22AC41A
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Fig. 9 | Michaelis-Menten curve for Co-BsLuxS-HT C22AC41A. The Michaelis-Menten curve for the mutant 
Co-BsLuxS-HT C22AC41A is shown. The kinetic parameters determined were: KM value = 0.1 ± 1.1 µM, Vmax = 
0.6 x 10-5 µmol/s and the kcat = 0.001 ± 0.08 M-1s-1. 
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Fig. 10 | Michaelis-Menten curve for Co-BsLuxS-HT C22AC126A. The Michaelis-Menten curve for the 
mutant Co-BsLuxS-HT C22AC126A. Mutant was determined to have no enzymatic activity. 
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Michaelis-Menten curve for
 Co-BsLuxS-HT C41AC126A
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Fig. 11 | Michaelis-Menten curve for Co-BsLuxS-HT C41AC126A. The Michaelis-Menten curve for the 
mutant Co-BsLuxS-HT C22AC126A is shown. Mutant was determined to have no enzymatic activity. 
Michaelis-Menten curve for
 Co-BsLuxS-HT C22AC41AC84A
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Fig. 12 | Michaelis-Menten curve for Co-BsLuxS-HT C22AC41AC84A. The Michaelis-Menten curve for Co-
BsLuxS-HT C22AC41A C84A is shown. The kinetic parameters determined were: KM value = 2.1 ± 5.6 µM, Vmax 
= 0.4 x 10-5 µmol/s and the kcat = 0.005 ± 0.002 M-1s-1.  
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Fig. 13 | Michaelis-Menten curve for Co-BsLuxS-HT C41AC126AC84A. The Michaelis-Menten curve for the 
mutant Co-BsLuxS-HT C41AC126A C84A is shown. The determined kinetic parameters were: KM value = 0.3 ± 
1.2 µM, Vmax = 0.4 x 10-5 µmol/s and the kcat = 0.005 ± 0.002 M-1s-1. 
Michaelis-Menten curve for
 Co-BsLuxS-HT T29C
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Fig. 14 | Michaelis-Menten curve for Co-BsLuxS-HT T29C. The Michaelis-Menten curve for the mutant Co-
BsLuxS-HT T29C is shown. The kinetic parameters determined were: KM  = 24 ± 112 µM, Vmax = 0.8 x 10-5 
µmol/s and the kcat = 0.012 ± 0.002 M-1s-1. 
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 Michaelis-Menten Curve for
Co-BsLuxS-HT Y71C Round 1
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Fig. 15 | Michaelis-Menten curve for Co-BsLuxS-HT Y71C Round 1. The Michaelis-Menten curve for Co-
BsLuxS-HT Y71C in round 1 is shown. The kinetic parameters determined were: KM = 4.5 ± 2.8 µM, Vmax = 1.12 
x 10-5 µmol/s and kcat = 0.015 ± 0.05 M-1s-1. The red dot is an outlier determined by graph pad prism 5.0. 
Michaelis-Menten Curve for
Co-BsLuxS-HT Y71C Round-2
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Fig. 16 | Michaelis-Menten curve for Co-BsLuxS-HT Y71C Round 2. The Michaelis-Menten curve for Co-
BsLuxS-HT Y71C in round 2 is shown. The kinetic parameters determined were: KM = 2 ± 1 µM , Vmax = 0.9 x 10-
5 µmol/s and kcat = 0.012 ± 0.05 M-1s-1.  
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 Michaelis-Menten Curve for
Co-BsLuxS-HT Y71C Round 3
0 10 20 30 40 50 60 70
0
10
20
30
40
50
[SRH] μM
R
ea
ct
io
n 
ra
te
s 
V 
( x
 1
0-
3 )
μ m
ol
/m
g/
m
in
 
Fig. 17 | Michaelis-Menten curve for Co-BsLuxS-HT Y71C Round 3. The Michaelis-Menten’s curve for the 
mutant Co-BsLuxS-HT Y71C in round 3 is shown. The kinetic parameters determined were: KM= 5.9 ± 2.2 µM, 
Vmax = 0.9 x 10-5 µmol/s and kcat = 0.01 ± 0.03 M-1s-1. 
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